Guidelines on the Radical Management of Patients with Lung Cancer

British Thoracic Society and the Society for Cardiothoracic Surgery in Great Britain and Ireland
Guidelines on the Radical Management of Patients with Lung Cancer

Eric Lim, David Baldwin, Michael Beckles, John Duffy, James Entwisle, Corinne Faivre-Finn, Keith Kerr, Alistair Macfie, Jim McGuigan, Simon Padley, Sanjay Popat, Nicholas Screaton, Michael Snee, David Waller, Chris Warburton, Thida Win

On behalf of the British Thoracic Society and Society for Cardiothoracic Surgery in Great Britain and Ireland Lung Cancer Guideline Group: a sub-group of the British Thoracic Society Standards of Care Committee
Aims and Scope: Thorax enjoys an enviable and longstanding reputation for publishing clinical and experimental research articles covering many disciplines, including pathology, immunology and surgery.

Editorial Board

E Abraham (USA)
A Agusti (Spain)
H Aranibar (Chile)
E Baraldi (Italy)
E Bateman (South Africa)
R Beasley (New Zealand)
J Bradley (UK)
J Britton (UK)
J de Jongste (Netherlands)
O E Fox (Germany)
J Fahy (USA)
J Gaudie (Canada)
M Han (USA)
J Henderson (UK)
F Holguín (USA)
R Kalhan (USA)
A Knox (UK)
C Kuehn (Switzerland)
G Lack (UK)
F Maltais (Canada)
F Martinez (USA)
N Maskell (UK)
A Morice (UK)
P O’Byrne (Canada)
M Peters-Golden (USA)
C Pison (France)
P Pizichini (Canada)
A Quittner (USA)
F Ratjen (Canada)
J Scullion (UK)
J Simpson (UK)
R Stein (Brazil)
R Taylor (New Zealand)
M Thomas (UK)
T Troosters (Belgium)
C Wainwright (Australia)
D Warburton (USA)
A Woodcock (UK)

Subscription Information

Thorax is published monthly (subscribers receive all supplements)

Institutional Rates 2010

<table>
<thead>
<tr>
<th>Print</th>
<th>£491; US$957; €663</th>
</tr>
</thead>
</table>
| Online         | Site licences are priced on FTE basis and allow access by the whole institution. Print is available at deeply discounted rates for online subscribers; details available online at [http://group.bmj.com/group/subs-sales/subscriptions](http://group.bmj.com/group/subs-sales/subscriptions) or contact the Subscription Manager in the UK (see above right).
|                | Personal print or online only and institutional print subscriptions may be purchased online at [http://group.bmj.com/group/subs-sales/subscriptions](http://group.bmj.com/group/subs-sales/subscriptions) (payment by MasterCard/Visa only).
|                | Residents of some EC countries must pay VAT, for details call us or visit [http://group.bmj.com/group/subs-sales/subscriptions/subs-vat](http://group.bmj.com/group/subs-sales/subscriptions/subs-vat)

Personal Rates 2010

<table>
<thead>
<tr>
<th>Print (includes online access and no additional cost)</th>
<th>£209; US$408; €282</th>
</tr>
</thead>
<tbody>
<tr>
<td>Online only</td>
<td>£115; US$224; €155</td>
</tr>
<tr>
<td>ISSN 0040-6376 (print)</td>
<td>ISSN 1468-3296 (online)</td>
</tr>
</tbody>
</table>

Contact Details

Editorial Office
BMJ Publishing Group Ltd, BMA House, Tavistock Square London, WC1H 9JR, UK
T: +44 (0)20 7383 6168
E: thorax@bmjgroup.com

Permissions
See [http://journals.bmj.com/misc/permissions.dtl](http://journals.bmj.com/misc/permissions.dtl)

Supplement Enquiries
T: +44 (0)20 7383 6057
F: +44 (0)20 7383 6402
E: cfolkes@bmjgroup.com

For ALL subscription enquiries and orders
T: +44 (0)20 7383 6270
F: +44 (0)20 7383 6402
E: support@bmjgroup.com
[http://group.bmj.com/group/customerservice/journalhelp](http://group.bmj.com/group/customerservice/journalhelp)

Advertising
T: +44 (0)20 7383 6386
F: +44 (0)20 7383 6556
E: ngray@bmjgroup.com
[http://group.bmj.com/group/ads](http://group.bmj.com/group/ads)

Author Reprints
Reprints Administrator
T: +44 (0)20 8445 5825
F: +44 (0)7866 262344
E: admin.reprints@bmjgroup.com

Commercial Reprints (UK & Canada)
Nadia Gurney-Randall
T: +44 (0)20 8445 5825
M: +44 (0)7866 262344
F: +44 (0)20 8445 5870
E: ngurneyrandall@bmjgroup.com

Commercial Reprints (USA & Canada)
Marsha Fogler
T: +1 856 489 4449 (toll free in the USA)
F: +1 856 489 4449 (outside the USA)
E: mfogler@medicalreprints.com

British Thoracic Society
17 Doughty Street
London WC1N 2PL, UK
T: +44 (0)20 7831 8766
F: +44 (0)20 7831 8766
E: bts@brit-thoracic.org.uk

---

Thorax is an international journal of respiratory medicine.
iii1 Synopsis of recommendations

iii3 Introduction

III4 Section 1: Selection of patients for radical treatment

1.1 Diagnosis and staging

1.1.1 Imaging

1.1.1.1 Plain radiography

1.1.1.2 Computed tomography (CT)

1.1.1.3 Positron emission tomography (PET) and PET-CT

1.1.1.4 Other imaging techniques

1.1.1.5 Evaluation of distant metastases

1.1.1.6 Small cell lung cancer

1.1.2 Endoscopic procedures for diagnosis and staging

1.1.2.1 Bronchoscopy

1.1.2.2 Blind TBNA, EBUS TBNA and EUS

1.1.2.3 Narrow band imaging and autofluorescence imaging

1.1.2.4 Video-assisted thoracoscopic assessment

1.1.2.5 Approach to mediastinal lymph node staging

1.1.2.6 Medistinoscopy and mediastinotomy

1.1.3 7th Edition of TNM for lung tumours

1.2 Management of specific disease subsets

1.2.1 T3 disease

1.2.2 T4 disease

1.2.3 N2 disease

1.2.4 M1 disease

1.2.5 M1 disease

1.2.6 Bronchialalveolar carcinoma

1.2.7 Open and close thoracotomy

2.1 Assessment of the risks of surgery

2.1.1 Risk assessment for operative mortality

2.1.2 Risk assessment for cardiovascular morbidity

2.1.3 Assessment of lung function

2.1.3.1 Split lung function testing

2.1.3.2 Exercise testing

2.1.4 Postoperative quality of life/dyspnoea

2.2 Surgical approach

2.2.1 Pulmonary resection

2.2.1.1 Estimating post-resection lung function

2.2.1.2 Bronchoplasticy and angioplastic resections

2.2.1.3 Sublobar resections

2.2.1.4 Combined lung volume reduction surgery

2.2.2 Lymph node management

2.3 Chemotherapy

2.3.1 Preoperative chemotherapy

2.3.2 Postoperative chemotherapy

2.4 Postoperative radiotherapy

iii17 Section 3: Radical radiotherapy

3.1 Assessment of the risks of radiotherapy

3.1.1 Risks of radical radiotherapy

3.1.2 Lung function assessment

3.2 Radiotherapy and chemoradiotherapy regimens

3.2.1 Early stage disease

3.2.2 Locally advanced disease

3.2.2.1 Patients eligible for concurrent chemoradiotherapy

3.2.2.2 Patients not eligible for concurrent chemoradiotherapy

3.2.2.3 Patients not eligible for chemotherapy

3.3 Other radical treatment

3.3.1 Radiofrequency ablation

3.3.2 Radical brachytherapy

iii19 Section 4: Small cell lung cancer

4.1 Chemoradiotherapy

4.1.1 Patients eligible for concurrent chemoradiotherapy

4.1.2 Patients not eligible for concurrent chemoradiotherapy

4.2 Surgery
Guidelines on the radical management of patients with lung cancer

Eric Lim,1 David Baldwin,2 Michael Beckles,3 John Duffy,2 James Entwistle,4 Corinne Faivre-Finn,5 Keith Kerr,6 Alistair Macfie,7 Jim McGuigan,8 Simon Padley,9 Sanjay Popat,10 Nicholas Screaton,11 Michael Snee,12 David Waller,13 Chris Warburton,14 Thida Win,15 British Thoracic Society and the Society for Cardiothoracic Surgery in Great Britain and Ireland

ABSTRACT
A joint initiative by the British Thoracic Society and the Society for Cardiothoracic Surgery in Great Britain and Ireland was undertaken to update the 2001 guidelines for the selection and assessment of patients with lung cancer who can potentially be managed by radical treatment.

SYNOPSIS OF RECOMMENDATIONS
The recommendations of the Guideline Development Committee (GDC) are listed below and can be cross-referenced in the main document. The list includes recommendations for research denoted by the abbreviation RR. The recommendations should be read in conjunction with figure 1 (mediastinal diagnosis and staging), figure 2 (tripartite risk assessment) and figure 3 (risk assessment for postoperative dyspnoea).

SECTION 1: SELECTION OF PATIENTS FOR RADICAL TREATMENT
1.1 Diagnosis and staging
1.1.1 Imaging
1. View all available historical images at the onset of the diagnostic pathway and review them prior to treatment. [C]
2. Ensure contemporaneous imaging is available at the time of radical treatment. [C]
3. Ensure a CT scan that is <4 weeks old is available at the time of radical treatment of borderline lesions. [D]
4. Arrange a CT scan of the chest, lower neck and upper abdomen with intravenous contrast medium administration early in the diagnostic pathway for all patients with suspected lung cancer potentially suitable for radical treatment. [C]
5. Avoid relying on a CT scan of the chest as the sole investigation to stage the mediastinal lymph nodes. [B]
6. Ensure positron emission tomography (PET)-CT scanning is available for all patients being considered for radical treatment. [B]
7. Offer radical treatment without further mediastinal lymph node sampling if there is no significant uptake in normal sized mediastinal lymph nodes on PET-CT scanning. [C]
8. Evaluate PET positive mediastinal nodes by further mediastinal sampling. [C]
9. Confirm the presence of isolated distant metastases/synchronous tumours by biopsy or further imaging in patients being considered for radical treatment. [D]
10. Consider MRI or CT scanning of the head in patients selected for radical treatment, especially in stage III disease. [C]
11. Evaluate patients with features suggestive of intracranial pathology by an initial CT scan of the head followed by MRI if normal or MRI as an initial test. [C]
12. Biopsy adrenal lesions that show abnormal uptake on PET-CT scanning before radical treatment. [D]
13. RR The role of PET-CT scanning in patients with small cell lung cancer considered suitable for radical treatment should be evaluated in clinical trials.

1.1.2 Endoscopic procedures for diagnosis and staging
14. When obtaining diagnostic and staging samples, consider the adequacy of these in the context of selection of patients for targeted therapy. [D]
15. Ensure biopsy samples are taken in adequate numbers and size where there is negligible additional risk to the patient. [D]
16. Use transbronchial needle aspiration (TBNA) and endobronchial ultrasound/endoscopic ultrasound (EBUS/EUS)-guided TBNA as an initial diagnostic and staging procedure according to findings on CT or PET-CT scans. [C]
17. Consider EBUS/EUS-guided TBNA to stage the mediastinum. [C]
18. Confirm negative results obtained by TBNA and EBUS/EUS-guided TBNA by mediastinoscopy and lymph node biopsy where clinically appropriate. [C]
19. RR The use of narrow band and autofluorescence imaging should be investigated in clinical trials.

1.1.3 7th Edition of TNM for lung tumours
20. The 7th edition of the TNM classification of lung cancer should be used for staging patients with lung cancer. [B]
21. The IASLC international nodal map should be used in the assessment and staging of lymph node disease. [C]

1.2 Management of specific disease subsets
1.2.1 T3 disease
22. Offer patients with T3N0–M0 disease radical treatment. [D]
1.2.2 T4 disease
23. Consider selected patients with T4N0–1M0 disease for radical multimodality treatment. \( [D] \)
24. RR Consider clinical trials of radical treatment for T4 disease.

1.2.3 N2 disease
25. Consider radical radiotherapy or chemoradiotherapy in patients with T1–4N2 (bulky or fixed) M0 disease. \( [B] \)
26. Consider surgery as part of multimodality management in patients with T1–3N2 (non-fixed, non-bulky, single zone) M0 disease. \( [B] \)
27. RR Consider further randomised trials of surgery added to multimodality management in patients with multi-zone N2 disease to establish if any subgroups of patients might benefit more from the addition of surgery.

1.2.4 N3 disease
28. RR Consider clinical trials of radical treatment for patients with T1–4N3M0 disease.

1.2.5 M1 disease
29. RR Consider clinical trials of radical treatment for patients with M1a and M1b disease.

1.2.6 Bronchioalveolar carcinoma
30. Offer suitable patients with single-site bronchioalveolar carcinoma anatomical lung resection. \( [C] \)
31. Consider multiple wedge resections in suitable patients with a limited number of sites of bronchioalveolar carcinoma. \( [C] \)

1.2.7 Open and close thoracotomy
32. Surgical units should have an open and close thoracotomy rate of around 5%. \( [D] \)

SECTION 2: SURGERY

2.1 Assessment of the risks of surgery
2.1.1 Risk assessment for operative mortality
33. Consider using a global risk score such as Thoracoscore to estimate the risk of death when evaluating and consenting patients with lung cancer for surgery. \( [C] \)

2.1.2. Risk assessment for cardiovascular morbidity
34. Use the American College of Cardiology guidelines 2007 as a basis for assessing perioperative cardiovascular risk. \( [C] \)
35. Avoid lung resection within 30 days of myocardial infarction. \( [B] \)
36. Seek a cardiology review in patients with an active cardiac condition or ≥3 risk factors or poor cardiac functional capacity. \( [C] \)
37. Offer surgery without further investigations to patients with ≤2 risk factors and good cardiac functional capacity. \( [B] \)
38. Begin optimisation of medical therapy and secondary prophylaxis for coronary disease as early in the patient pathway as possible. \( [C] \)
39. Continue anti-ischaemic treatment in the perioperative period including aspirin, statins and β blockade. \( [B] \)
40. Discuss management of patients with a coronary stent with a cardiological to determine perioperative antiplatelet management. \( [C] \)
41. Consider patients with chronic stable angina and conventional ACC/AHA indications for treatment (coronary artery bypass grafting and percutaneous coronary intervention) for revascularisation prior to thoracic surgery. \( [C] \)

2.1.3 Assessment of lung function
42. Measure lung carbon monoxide transfer factor in all patients regardless of spirometric values. \( [C] \)
43. Offer surgical resection to patients with low risk of postoperative dyspnoea. \( [C] \)
44. Offer surgical resection to patients at moderate to high risk of postoperative dyspnoea if they are aware of and accept the risks of dyspnoea and associated complications. \( [D] \)
45. Consider using ventilation scintigraphy or perfusion scintigraphy to predict postoperative lung function if a ventilation or perfusion mismatch is suspected. \( [C] \)
46. Consider using quantitative CT or MRI to predict postoperative lung function if the facility is available. \( [C] \)
47. Consider using shuttle walk testing as functional assessment in patients with moderate to high risk of postoperative dyspnoea using a distance walked of >400 m as a cut-off for good function. \( [C] \)
48. Consider cardiopulmonary exercise testing to measure peak oxygen consumption as functional assessment in patients with moderate to high risk of postoperative dyspnoea using >15 ml/kg/min as a cut-off for good function. \( [D] \)
49. RR Further studies with specific outcomes are required to define the role of exercise testing in the selection of patients for surgery.

2.1.4 Postoperative quality of life/dyspnoea
50. Avoid pneumonectomy where possible by performing bronchoangioplasty resection or non-anatomical resection. \( [C] \)
51. Avoid taking pulmonary function and exercise tests as sole surrogates for quality of life evaluation. \( [C] \)
52. When estimating quality of life, use a validated instrument. \( [D] \)

2.2 Surgical approach
2.2.1 Pulmonary resection
53. Employ segment counting to estimate postoperative lung function as part of risk assessment for postoperative dyspnoea. \( [D] \)
54. Consider patients with moderate to high risk of postoperative dyspnoea for lung parenchymal sparing surgery. \( [D] \)
55. Consider bronchoangioplasty procedures in suitable patients to preserve pulmonary function. \( [D] \)
56. Consider patients with limited pulmonary reserve for sublobar resection as an acceptable alternative to lobectomy. \( [B] \)
57. RR Consider randomised trials of segmental resection versus wedge resection.
58. Consider patients with concomitant lung cancer within severe heterogeneous emphysema for lung resection based on lung volume reduction surgery criteria. \( [B] \)

2.2.2 Lymph node management
59. Perform systematic nodal dissection in all patients undergoing resection for lung cancer. \( [A] \)
60. Remove or sample a minimum of six lymph nodes or stations. \( [D] \)

2.3 Chemotherapy
2.3.1 Preoperative chemotherapy
61. Patients with resectable lung cancer should not routinely be offered preoperative chemotherapy. \( [B] \)

2.3.2 Postoperative chemotherapy
62. Offer postoperative chemotherapy to patients with TNM 7th edition T1–5N1–2M0 non-small cell lung cancer. \( [A] \)
63. Consider postoperative chemotherapy in patients with TNM 7th edition T2—N0M0 non-small cell lung cancer with tumours >4 cm diameter. [B]

64. Use a cisplatin-based combination therapy regimen in postoperative chemotherapy. [A]

65. RR Consider further trials of novel chemotherapeutic agents in conjunction with surgical resection.

2.4 Postoperative radiotherapy

66. Postoperative radiotherapy (PORT) is not indicated after R0 complete resection. [A]

67. Consider PORT for patients with residual microscopic disease at the resection margin where the benefit of reduction in local recurrence outweighs the risk of mortality and morbidity related to PORT. [C]

68. Use CT-planned three-dimensional conformal radiotherapy for patients receiving PORT. [B]

69. Consider PORT after completion of adjuvant chemotherapy. [B]

70. RR Randomised trials looking at the effect of PORT in pN2 non-small cell lung cancer are recommended.

SECTION 3: RADICAL RADIOTHERAPY
3.1 Assessment of the risks of radiotherapy

3.1.1 Risks of radical radiotherapy

71. Perform three-dimensional treatment planning in patients undergoing radical thoracic radiotherapy. [B]

72. A clinical oncologist specialising in lung oncology should determine suitability for radical radiotherapy, taking into account performance status and comorbidities. [D]

73. RR Clinical trials of radical radiotherapy should include measures of lung function, outcome and toxicity.

3.2 Radiotherapy and chemoradiotherapy regimens

3.2.1 Early stage disease

74. Offer radical radiotherapy to patients with early stage non-small cell lung cancer who have an unacceptable risk of surgical complications. [B]

75. Consider CHART as a treatment option in patients with early stage non-small cell lung cancer and unacceptable risk of surgical complications. [A]

76. Consider stereotactic body irradiation in patients with early stage non-small cell lung cancer and unacceptable risk of surgical complications. [C]

3.2.2 Locally advanced disease

77. Offer chemoradiotherapy to patients with locally advanced non-small cell lung cancer and good performance status who are unsuitable for surgery. [A]

78. Offer selected patients with good performance status concurrent chemoradiotherapy with a cisplatin-based chemotherapy combination. [A]

79. Offer patients unsuitable for concurrent chemoradiotherapy sequential chemoradiotherapy. [A]

80. Consider CHART as a treatment option for patients with locally advanced non-small cell lung cancer. [A]

3.3 Other radical treatment

81. RR Randomised controlled trials are recommended comparing conventional radical treatment (surgery, radical radiotherapy) with other radical treatments where there is evidence of efficacy in case series.

82. Consider alternative radical treatment in early stage lung cancer in patients at high risk of morbidity and mortality with conventional radical treatment. [D]

83. Consider radical brachytherapy in patients with early invasive mucosal or submucosal non-small cell lung cancer. [D]

SECTION 4: SMALL CELL LUNG CANCER
4.1 Chemoradiotherapy

84. Offer selected patients with T1—4N0—3M0 limited stage small cell lung cancer both chemotherapy and radiotherapy. [A]

85. Offer patients with T1—4N0—3M0 limited stage small cell lung cancer and good performance status concurrent chemoradiotherapy. [A]

86. Recommended treatment options for concurrent chemoradiotherapy are twice daily thoracic radiotherapy (45 Gy in 5-weeks) with cisplatin and etoposide and 40 Gy once daily delivered in 3 weeks. [A]

87. Offer patients unsuitable for concurrent chemoradiotherapy sequential chemoradiotherapy. [A]

88. Offer prophylactic cranial irradiation to patients with response to treatment and stable disease. [A]

4.2 Surgery

89. Consider patients with T1—SN0—1M0 small cell lung cancer for surgery as part of multi-modality management. [D]

90. Surgical management of patients with T1—3N2M0 small cell lung cancer should only be considered in the context of a clinical trial. [C]

SECTION 5: PROVISION OF TREATMENT OPTIONS

91. All available treatment options, including those that are the subject of research, should be discussed with patients and their carers and the risks and benefits presented so that they may make an informed choice. [D]

INTRODUCTION

This document is the result of a joint initiative by the British Thoracic Society (BTS) and the Society for Cardiothoracic Surgery in Great Britain and Ireland (SCTS) to update the 2001 guidelines for the selection and assessment of patients with lung cancer1[N/A] who can potentially be managed by radical treatment. In the previous guidelines it was hoped that more uniform selection and assessment might lead to improvement in resection and survival rates of patients with lung cancer. Despite good uptake of the guidelines, data from the 2008 National Lung Cancer Audit show that the lung resection rate in the UK was 11% and that there was considerable variation between networks (from 5% to >25%).2[N/A] Lung cancer survival in the UK is still among the lowest in Europe.3[N/A]

Changes to the layout and approach of this update are intended to provide comprehensive guidance on selection (by stage criteria) and risk assessment but also on the wider management of patients suitable for radical treatment. The treatment options have also become less distinct with a move towards multi-modality management. The risk assessment algorithm was revised to take into consideration not only mortality but also postoperative dyspnoea, an outcome of great importance to the patient. In accordance with General Medical Council recommendations,4[N/A] risks of treatments are presented to allow patients to weigh risks and benefits of each modality and facilitate a joint clinician—patient decision making process.

Definition of radical and palliative treatment

The Guideline Development Committee (GDC) considered it important to clarify the definition of radical and palliative
treatment, as some recommendations are based on the management intent. Thus, radical treatment is defined as treatment given with the intention to improve survival substantially, which may amount to a cure. Palliative treatment is defined as treatment given with the intention to improve quality of life and may include prolonging the length of life as a secondary benefit.

The terms ‘operable’ and ‘resectable’
The GDC noted that these terms were used by some multidisciplinary teams (MDTs). ‘Resectable’ indicates that the primary tumour can be completely excised by surgery with clear pathological margins. ‘Operable’ indicates that the patient has an acceptable risk of death or morbidity. These terms are useful to focus attention on these aspects of surgical treatment. However, MDTs and patients may have different thresholds for operability and surgeons may have different thresholds for resection. What is important is the parameters set to define thresholds and the implication for the patient in terms of mortality and morbidity. This guideline has therefore not used these terms but rather addressed the thresholds, indicating where patient choice may be pivotal.

Guideline development
The scope of the guideline was determined by the GDC and based on the previous guideline and consultation with both societies and with input from members from associated specialities including radiology, anaesthesia and pathology. The topics covered by the scope are listed in appendix 1. The comprehensive search strategy (see appendix 2 in online supplement) found over 5500 references revealed that, since the publication of the 2001 guidelines, the evidence base for selection and management of patients suitable for radical treatment increased considerably. Evidence was graded according to the Scottish Intercollegiate Guidelines Network (SIGN) system (appendix 3). References are followed by the level of evidence in square brackets. Where it is not appropriate to apply SIGN levels, the brackets contain N/A (not applicable).

The aim of this updated guideline is to assist in raising standards of the delivery of radical treatments in the UK. The draft document was circulated to the membership of the BTS, the membership of the SCTS, and presented at BTS, SCTS and British Thoracic Oncology Group meetings. Comments were incorporated into the final draft from the Royal College of Physicians, the Association of Cancer Physicians, the Royal College of Anaesthesia and Royal College of Pathologists.

The guidelines will be reviewed 3 years from the date of publication.

SECTION 1: SELECTION OF PATIENTS FOR RADICAL TREATMENT

1.1 Diagnosis and staging
The selection of patients for radical treatment requires an investigation pathway directed towards providing as much diagnostic and staging information as possible. This is particularly important in patients who are at risk of post-treatment complications and those where it is unclear if complete surgical resection or radical radiotherapy can be successfully delivered. However, in patients without a positive histological diagnosis and at low risk of complications, surgical treatment may be offered on a presumptive basis in patients following a limited number of essential tests. It is important that the logic underlying this approach is discussed with the patient and the consequences of resection of a benign lesion discussed. It is best practice for the diagnosis to be confirmed prior to definitive surgical resection. Treatment with radical radiotherapy or chemoradiotherapy usually requires a pretreatment diagnosis because no specimens are obtained as part of the treatment. Diagnostic samples will need to be sufficient to allow adequate classification of tumours, especially given the possibility of targeted treatment.

In this document, the 7th edition of the TNM classification of lung cancer is used throughout and applies to non-small cell lung cancer, small cell lung cancer and pulmonary neuroendocrine tumours. Almost all of the evidence upon which recommendations are made relates to the 6th edition.

1.1.1 Imaging
Imaging plays an essential role in establishing an accurate diagnosis and stage for patients with lung cancer. The current pace of technological development is rapid and consequently the evidence for the effectiveness of the newer techniques such as multidetector CT, positron emission tomography (PET) and PET-CT is limited. Moreover, much of the evidence on cost-effectiveness for lung cancer is derived from studies conducted outside the UK and so their applicability to the UK healthcare system is limited.

Contemporaneous imaging
All diagnostic images should be available to the multidisciplinary team to allow the evaluation of growth rate/malignant potential of a tumour. The absence of growth over 2 years suggests a benign lesion. When delays occur as a result of additional tests, imaging may need to be repeated, especially when initial imaging indicates a borderline lesion for resection (eg, T3/4). While there is no evidence for an acceptable interval, it is recommended as a minimum for patients with a T3/T4 tumour that a CT scan <4 weeks old is available at the time of radical treatment.

Recommendations
- View all available historical images at the onset of the diagnostic pathway and review them prior to treatment. [C]
- Ensure contemporaneous imaging is available at the time of radical treatment. [C]
- Ensure a CT scan that is <4 weeks old is available at the time of radical treatment of borderline lesions. [D]

1.1.1.1 Plain radiography
A plain x-ray (high quality posteroanterior image) is an essential tool for initial investigation of symptoms that might indicate lung cancer, but only has a minimal contribution to diagnosis and staging once it has been decided to proceed to CT. A routine lateral image is not required.

1.1.1.2 Computed tomography (CT)
CT is the initial imaging modality of choice for diagnosis and staging of suspected lung cancer, and serves as a tool for triage that determines the most appropriate further investigation. CT also provides information on coexistent disease such as emphysema, pulmonary embolism, cardiac and vascular disease. Multidetector CT (MDCT) with administration of intravenous contrast medium (in the absence of contraindications) provides rapid coverage of the chest and upper abdomen, and multiplanar image reconstruction may be helpful in demonstrating tumour anatomy, location and volume for staging. The extent of CT coverage should include the lower neck (defined as the level of the vocal cords) for the detection of supraclavicular nodal
Several studies have shown that tumours can be detected with various imaging modalities. A number of small studies indicate that PET-CT is equal or superior to PET alone. Limitations of the technique are well recognised. False negative scans may result from disease with low metabolic activity or FDG uptake (carcinoid, bronchioloalveolar cell carcinoma), misregistration due to breathing artefact, uncontrolled diabetes and small lesion size (<8 mm), and false positive uptake may be seen in inflammatory conditions. Nevertheless, PET now has an established role in the evaluation of patients for radical treatment.

PET-CT is valuable in assigning a T stage and also for radiotherapy planning (table 1). However, in proximal tumours both CT and PET techniques may have difficulty differentiating the primary tumour from contiguous lymphadenopathy.

PET is more accurate than CT in assessing lymph node status (table 1). False negative results can occur either due to small volume disease or low metabolic activity. Sampling of enlarged PET-CT negative nodes is generally advocated, particularly when the primary tumour uptake is intermediate (see section on N2 disease). False positive results can occur due to inflammation, especially if there is associated coexistent disease such as consolidation distal to the tumour.

PET-CT misses very few occult macroscopic metastases except in the brain (table 1). False positives do occur and patients should not be denied radical treatment on the basis of occult metastatic disease on PET-CT alone (especially if it is isolated). Confirmation by biopsy or further imaging is required. By inference, from the fact that around 20% of patients go on to develop distant metastases despite complete resection of the primary tumour, PET-CT does miss micrometastases. However, there are no other reliable methods to detect these.

Prognostic information. Several studies have shown that tumours with an increased metabolic activity measured by maximal standardised uptake value (SUVmax) have a worse prognosis. Based on limited available evidence, SUVmax should be reported but not influence the decision to offer radical treatment. When assessing the mediastinal lymph nodes after induction treatment for patients with stage IIIA non-small cell lung cancer, a negative PET is less reliable than a pretreatment scan but may be more reliable than repeat mediastinoscopy.\[^{2,2}^{+}\]

Radiotherapy planning. Evidence to support the use of PET or PET-CT prior to radical radiotherapy is limited. In a report evaluating

<p>| Table 1 Role of commonly used imaging modalities in the diagnosis and staging of patients suitable for radical treatment |
|---|---|---|---|---|</p>
<table>
<thead>
<tr>
<th>Imaging modality</th>
<th>Diagnosis</th>
<th>T stage</th>
<th>N stage</th>
<th>M stage</th>
<th>Comment</th>
</tr>
</thead>
<tbody>
<tr>
<td>Chest x-ray</td>
<td>Often included as part of initial investigation in primary care and useful to differentiate benign from malignant disease</td>
<td>Limited information compared with MDCT</td>
<td>Provides little information</td>
<td>Obvious metastases may be visible (eg, lung or rib)</td>
<td>Now sometimes omitted from investigation pathway if other presenting factors suggest cancer*</td>
</tr>
<tr>
<td>MDCT</td>
<td>Often helpful to differentiate benign from malignant disease</td>
<td>Able to measure tumour size accurately. Less reliable for distinguishing T3 from T4; 55% sensitivity, 89% specificity (axial CT)</td>
<td>Significantly enlarged nodes (&gt;10 mm short axis) easily defined. However, about 40% of these are benign and 20% of nodes, &lt;10 mm are malignant.[^{1}] Sensitivity 57–61%, specificity 79–82%.[^{12,13}]</td>
<td>May show clear evidence of mediastinal invasion or metastatic disease but histological confirmation or further staging required if any doubt</td>
<td>Provides excellent triage of patients by identifying clear evidence of cancer, no evidence of cancer ± other diagnoses or uncertainty. Guides the next test. May detect other significant coexistent disease</td>
</tr>
<tr>
<td>PET-CT</td>
<td>Not currently performed for initial diagnostic purposes</td>
<td>Complements MDCT and can help estimate tumour extent where tumour abuts abnormal tissue (eg, lobar collapse)</td>
<td>More accurate than CT. Sensitivity 84%, specificity 89%. Further mediastinal sampling deemed unnecessary if PET negative and nodes &lt;1 cm.[^{1}] 10% will have occult disease[^{4}]</td>
<td>Sensitivity and specificity to detect distant metastases 93% and 96%, respectively. May detect metastases in up to 15%. Sensitivity for brain metastases only 60%.[^{17–21}]</td>
<td>Also useful in radiotherapy planning and may have a role in predicting outcome[^{14–16}]</td>
</tr>
</tbody>
</table>

---

*Careful review of serial changes may help differentiate benign from malignant disease.
\[The prevalence of false negatives increases with later stage disease.\]
MDCT, multidetector computed tomography; PET-CT, positron emission tomography-computed tomographyc.

---

Thorax 2010;65(Suppl III):iii1—iii27. doi:10.1136/thx.2010.145938

ii5
the economic impact of PET for radiotherapy planning, it was noted that the use of PET resulted in 32% fewer courses of futile radical radiotherapy.\textsuperscript{26,N/A} PET-CT has also been shown to modify potential fields in radiotherapy planning.\textsuperscript{14[3]},\textsuperscript{15[2–1],16[2+]} although there are few outcome data to confirm that this is effective.

**Recommendations**

- Ensure PET-CT is available for all patients being considered for radical treatment. \textbf{[B]}
- Offer radical treatment without further mediastinal lymph node sampling if there is no significant uptake in normal sized mediastinal lymph nodes on PET-CT scanning. \textbf{[C]}
- Evaluate PET positive mediastinal nodes by further mediastinal sampling. \textbf{[C]}
- Confirm the presence of isolated distant metastases/synchronous tumours by biopsy or further imaging in patients being considered for radical treatment. \textbf{[C]}

### 1.1.1.4 Other imaging techniques

Further imaging and sampling may be required to clarify the tumour stage when more extensive disease is suspected from clinical features or initial investigations.

While CT is a sensitive method for detecting fluid in the pleura and pericardium, not all effusions are malignant so pathological confirmation by aspiration is required before excluding patients from radical treatment. Pleural enhancement is always abnormal and, although CT features of malignant pleural disease (such as circumferential pleural thickening, nodular thickening, parietal pleural thickening >1 cm and mediastinal pleural involvement) have limited sensitivity, they are highly specific for malignancy.\textsuperscript{31[3],27[3],28[3],29[2+],30[3]} The role of PET-CT scanning in patients with small cell lung cancer

---

**Table 2** Utility of commonly used imaging modalities

<table>
<thead>
<tr>
<th>Imaging modality</th>
<th>Scenario where radical treatment is considered</th>
</tr>
</thead>
<tbody>
<tr>
<td>MRI</td>
<td>To evaluate indeterminate lesions of the bone, adrenal glands and liver</td>
</tr>
<tr>
<td></td>
<td>To evaluate superior sulcus tumours: superior to axial CT, complementary\textsuperscript{18[3]} to MDCT</td>
</tr>
<tr>
<td>Ultrasound</td>
<td>To evaluate tumours in close proximity to spinal cord</td>
</tr>
<tr>
<td>Bone scintigraphy</td>
<td>To screen for bone metastases when there is clinical or biochemical evidence of bone metastases (PET may be avoided in the early diagnostic pathway)</td>
</tr>
</tbody>
</table>

MDCT, multidetector computed tomography; PET, positron emission tomography.

Adrenal glands. Adrenal lesions are commonly found on CT scans and many of these are benign. The likelihood of malignancy increases with primary tumour stage and adrenal lesion size.\textsuperscript{54[3]} PET is currently the most common method to distinguish between benign and malignant adrenal lesions with a sensitivity of 94–100% and specificity of 80–100%.\textsuperscript{35[2+],36[2–],37[2–],38[3],39[2–],40[2–],41[2–]} Blake et al reported a sensitivity and specificity of 100% and 95.8% for PET-CT, and this can be combined with contrast-enhanced CT to improve the specificity to 100%.\textsuperscript{41[2–]} However, this impressive performance may not be repeated in all centres and benign entities (eg, lipid-poor adenomas) may show increased uptake on PET and may be indeterminate on standard CT. In this setting, a biopsy is required to confirm the presence of metastastic disease. Other imaging options include in and out of phase MRI,\textsuperscript{42[2+]} non-contrast\textsuperscript{46[3]} and washout CT.\textsuperscript{42[2+]} Biopsy specimens may be obtained by percutaneous techniques,\textsuperscript{5[3]} endoscopic ultrasound or laparoscopy.

Liver. Indeterminate lesions in the liver identified on CT may mimic metastases, but most are benign cysts. Ultrasound, dynamic contrast-enhanced MRI or percutaneous biopsy may be performed for further evaluation.

Bones. PET is more sensitive in detecting bone metastases than conventional bone scintigraphy,\textsuperscript{46[2–]} and PET-CT is likely to be superior. The role of bone scintigraphy is limited to those with a high clinical suspicion of metastastic disease as a positive result will effectively exclude a patient from further radical treatment.

**Recommendation**

- Biopsy adrenal lesions that show abnormal uptake on PET-CT scanning before radical treatment. \textbf{[D]}

### 1.1.1.6 Small cell lung cancer

In early stage small cell lung cancer where radical treatment is contemplated, a number of studies indicate that PET,\textsuperscript{47[3],48[2–],49[1],50[2–],51[1],52[2–],53[3],54[3],55[2+],56[2–] and contrast-enhanced MRI of the brain\textsuperscript{57[3]} may pick up occult disease. However, most patients still undergo chemotherapy and radiotherapy as planned, and the role of PET-CT in these circumstances is not defined. These screening investigations should therefore be reserved for the small group of patients who present with early stage disease in whom radical management is contemplated and if the results of detection of occult disease would alter the management.

**Research recommendation**

- The role of PET-CT scanning in patients with small cell lung cancer considered suitable for radical treatment should be evaluated in clinical trials.
1.1.2 Endoscopic procedures for diagnosis and staging

Type of sample in relation to treatment planning

Emerging data on differential responses to chemotherapy according to non-small cell carcinoma subtype have heightened the emphasis on the need to obtain tissue that gives enough information to plan the best treatment. It is important that diagnostic samples enable distinction between squamous cell and adenocarcinoma if active treatment is to be offered. This distinction may require more in-depth evaluation using immunohistochemistry. Furthermore, emerging prognostic and/or predictive tumour markers, measured by immunohistochemistry, in situ hybridisation and mutation analysis, may be needed to inform therapeutic decisions. These additional analyses require a sample of adequate size, yet the trend towards less invasive sampling techniques for diagnosis and staging means samples are often more limited. Improved laboratory techniques may go some way to mitigate the problems of small samples but cannot overcome all the inherent limitations. These limitations need to be considered in the context of planned treatment and safety and there needs to be involvement of the histopathologist in the design of the diagnostic pathway.

Recommendation

- When obtaining diagnostic and staging samples, consider the adequacy of these in the context of selection of patients for targeted therapy. [D]
- Ensure biopsy samples are taken in adequate numbers and size where there is negligible additional risk to the patient. [D]

1.1.2.1 Bronchoscopy

Flexible bronchoscopy is a safe and effective diagnostic and staging investigation. As well as conventional biopsy, blind transbronchial needle aspiration (TBNA) can be performed to sample mediastinal lymph nodes. With central tumours, direct invasion and tumour relations to the main bronchus and trachea can be assessed and the information used to guide the extent of surgical resection required for complete clearance. Such information should be documented.

1.1.2.2 Blind transbronchial needle aspiration, endobronchial ultrasound transbronchial needle spiration and endoscopic ultrasound

Blind TBNA, endobronchial ultrasound (EBUS) TBNA and endoscopic ultrasound (EUS) are extensions of endoscopic techniques and are currently used for assessment and staging. Blind TBNA is an inexpensive way to screen for metastases in enlarged lymph nodes at stations 2, 4 and 7. This technique is guided by CT images and, although studies report a sensitivity of 60–70% for a simple diagnosis of malignancy, the results are operator-dependent. 58[2+]

EBUS can sample lymph node stations 2, 3, 4, 7, hilar station 10 and lobar station 11. EUS can sample lymph node stations 4L, 7, 8, 9, the left adrenal gland and the left lobe of the liver. Neither EBUS nor EUS are generally able to access the para-aortic station 6 or aortopulmonary station 5.

For EBUS TBNA, systematic reviews now report sensitivity and specificity for staging the mediastinal lymph nodes as 88–95% and 100%, respectively. 59[2+],60[1+] These results come from expert groups, and it is therefore important to consider if the local test performance is equivalent. If so, these procedures can be considered as alternatives to mediastinoscopy and lymph node biopsy. Mediastinoscopy is still performed to confirm negative results obtained by endoscopic biopsies, although this has to be balanced against the intended treatment (patients for radical radiotherapy may not be fit for general anaesthetic) and the local performance of EBUS or EUS.

Recommendations

- Use TBNA and EBUS/EUS-guided TBNA as an initial diagnostic and staging procedure according to findings on CT or PET-CT scans. [C]
- Consider EBUS/EUS-guided TBNA to stage the mediastinum. [C]
- Confirm negative results obtained by TBNA and EBUS/EUS-guided TBNA by mediastinoscopy and lymph node biopsy where clinically appropriate. [C]

1.1.2.3 Narrow band imaging and autofluorescence imaging

Autofluorescence bronchoscopy and narrow band imaging can detect early and preinvasive lesions. This may prove to be important when considering radical treatment of early endobronchial lesions with techniques such as endobronchial brachytherapy, cryotherapy and photodynamic therapy. The results of randomised trials are awaited.

Research recommendation

- The use of narrow band and autofluorescence imaging should be investigated in clinical trials.

1.1.2.4 Mediastinoscopy and mediastinotomy

Mediastinoscopy is the current gold standard procedure for staging the mediastinum prior to thoracotomy and systematic nodal dissection. The indications for cervical mediastinoscopy have evolved with the increasing availability of PET, EBUS, EUS and broader selection criteria for surgery. With a sensitivity of 85% for PET imaging, many consider that confirmatory mediastinoscopy and lymph node biopsies are not required following a ‘negative’ PET. Microscopic N2 disease may have a better prognosis, but this will only be confirmed if appropriate lymph node sampling is performed. Although the specificity of PET is high, minimally invasive sampling followed by mediastinoscopy is indicated to screen for false positive results in order not to deny the small proportion of patients the potential of radical treatment. As broader selection criteria are in place, the clinical utility of pretreatment lymph node staging has evolved to assess the location and number of lymph stations that are involved rather than the presence or absence of mediastinal lymph node metastases.

1.1.2.5 Video-assisted thoracoscopic assessment

Video-assisted thoracoscopic assessment can be used as a diagnostic and staging modality. Biopsies may be obtained from the tumour mass, direct ascertainment of tumour invasion into the central mediastinal structures can be performed and access can be obtained to the hilar, aortopulmonary window, paroesophageal and inferior pulmonary ligament stations. With the increasing diagnostic accuracy of CT, PET, EBUS and EUS for staging, the requirement for video-assisted thoracoscopic assessment is becoming less common, although it remains the best assessment to determine if it is possible to completely resect a tumour prior to thoracotomy.

1.1.2.6. Approach to mediastinal lymph node staging

The purpose of preoperative mediastinal staging is to assist in the selection of patients for radical treatment. The often pivotal question is whether or not there is disease in N2 or N3 stations. Disease in N1 nodes may change management according to the type of operation that can be performed in patients with borderline lung function. Most MDTs will agree that N3 disease precludes surgery, but radical treatment may still be possible. The MDT should decide whether or not the knowledge that
The 7th edition of the TNM classification of lung cancer should be used for staging patients with lung cancer. [B]

1.2 Management of specific disease subsets

There have been no randomised trials comparing the outcome of surgery compared with no intervention. Indirect evidence from the Early Lung Cancer Action Project (ELCAP), a large screening study for lung cancer, reported that all eight patients with screen-detected stage 1 lung cancer who did not have surgery died within 5 years while 92% of those who received surgical treatment survived 5 years. [2+1]

Based largely on retrospective and observational studies, radical management (surgery or radiotherapy in those who have an unacceptable surgical risk) is the accepted standard. The remainder of this section focuses on specific disease subgroups.

1.2.1 T3 disease

A T3 designation is assigned to tumours >7 cm in diameter or by virtue of local invasion or for separate nodules within the same lobe of the primary tumour. Acceptable results after radical treatment have been reported in those patients with involvement of the chest wall, mediastinum, heart, great vessels, trachea, recurrent laryngeal nerve, oesophagus, vertebral body, carina and for separate tumours in a different ipsilateral lobe. In the specific case of patients with separate tumours in a different ipsilateral lobe, the good survival in patients undergoing surgical resection led to downstaging of this subgroup in the 7th edition of TNM for lung tumours.

The majority in this subgroup with central mediastinal invasion have disease that is not amenable to surgery. However, centres with a specific interest and expertise in resection of locally advanced tumours invading into structures such as the spine, carina, heart and great vessels report technical feasibility and acceptable mid-term results, usually in the absence of N2 or M1 disease. An initial safety and feasibility study in patients with stage IIIA/IIIB disease undergoing induction chemoradiotherapy and surgery as part of multi-modality management has led to a phase II clinical trial reporting favourable survival in patients with T1-4N3M0 and T4N0-5M0 disease when compared with a historical cohort. While the results of the study are not conclusive for better outcomes, they highlight what can be achieved with appropriate case selection and multidisciplinary management.

Recommendations

- Consider selected patients with T4N0-1M0 disease for radical multimodality treatment. [D]

1.2.2 T4 disease

T4 designation is assigned to any tumour with invasion of the mediastinum, heart, great vessels, trachea, recurrent laryngeal nerve, oesophagus, vertebral body, carina and for separate tumours in a different ipsilateral lobe. In the specific case of patients with separate tumours in a different ipsilateral lobe, the good survival in patients undergoing surgical resection led to downstaging of this subgroup in the 7th edition of TNM for lung tumours.

The majority in this subgroup with central mediastinal invasion have disease that is not amenable to surgery. However, centres with a specific interest and expertise in resection of locally advanced tumours invading into structures such as the spine, carina, heart and great vessels report technical feasibility and acceptable mid-term results, usually in the absence of N2 or M1 disease. An initial safety and feasibility study in patients with stage IIIA/IIIB disease undergoing induction chemoradiotherapy and surgery as part of multi-modality management has led to a phase II clinical trial reporting favourable survival in patients with T1-4N3M0 and T4N0-5M0 disease when compared with a historical cohort. While the results of the study are not conclusive for better outcomes, they highlight what can be achieved with appropriate case selection and multidisciplinary management.

Recommendations

- Consider selected patients with T4N0-1M0 disease for radical multimodality treatment. [D]

Research recommendation

- Consider clinical trials of radical treatment for T4 disease.

1.2.3 N2 disease

N2 disease describes any metastatic involvement of ipsilateral or subcarinal mediastinal nodes. This term encompasses...
a spectrum of disease from micrometastatic disease in one node to extranodal extension from malignant disease in several lymph node stations. The management of N2 disease should therefore be considered separately for each subgroup with different prognoses.

The IASLC Lung Cancer Staging Project identified that overall disease burden (in the lymph nodes) had more influence on prognosis than anatomical site of lymph node involvement, hence nodal stations are now consolidated into lymph node zones. The prognosis of single zone N2 disease (N2a) was better than multi-zone N2 (N2b) disease with post-resection 5-year survivals of 34% and 20%, respectively (p<0.001).

The diagnostic and staging pathway in patients with N2 disease should be directed by the intended treatment. When radical treatment is not possible, histological confirmation of N2 disease is not required. When radical treatment is intended, investigations should proceed as described (section 1.1.2) with mediastinoscopy as the final gold standard to confirm the presence and location of N2 disease (as in many mediastinal stations as possible). Ideally, mediastinal lymph node staging in patients considered for radical radiotherapy should be as rigorous as that carried out in patients considered for surgery. This may, however, be difficult as these former patients tend to have more comorbidity.

Occult N2 disease

Occult N2 disease is found during or after resection. If preoperative PET-CT and/or mediastinoscopy have excluded N2 disease and positive N2 nodes are found at operation, the lymph nodes should be resected with the primary tumour and adjuvant chemotherapy should be considered separately for each subgroup with different prognoses.

Single zone N2 disease

Resection may be considered in patients with single zone N2 disease as survival is similar to patients with multi-zone N1b disease. There may also be a role for surgery when the tumour volume of the primary tumour plus nodal disease cannot be encompassed in a radical radiotherapy field. Surgery followed by chemotherapy in this setting may be an alternative to palliative treatment, although there is no direct evidence for this approach.

Multi-zone disease

Patients with bulky or fixed N2 disease are not considered for surgery and are treated by combinations of chemotherapy, radical radiotherapy or concurrent chemoradiotherapy.

For patients with non-fixed bulky multi-zone N2 disease, the results of a number of studies exploring induction treatment have been published with similar survival in patients randomised to surgery and chemotherapy or radiotherapy and chemotherapy. In a study of 579 patients in whom induction chemotherapy was administered, responders were randomised to surgery or radiotherapy and similar survival was reported between the two treatment modalities. A more recent study of induction chemoradiotherapy followed by surgical resection or radiotherapy in 396 patients, however, reported improved progression-free survival in patients randomised to surgery.

Results and outcomes based on response to induction treatment are less clear. The results from a meta-analysis indicate a survival advantage with surgical resection in patients downstaged to N0. However, it is the relative difference in survival in patients who have not been downstaged that is more important in the clinical decision. Albain et al. showed that, in patients who underwent surgery, the 5-year survival was 41% for N0 disease, 24% for N1–3 disease and 8% for those who did not undergo surgery (for whatever reason). From the available evidence, no management regimen has consistently proved superior. The GDC recognised that some patients with multi-zone N2 disease, having been fully appraised of the evidence, may wish to undergo surgery as part of multimodality management. The majority of the GDC felt that this option should be within the context of further randomised trials.

Recommendations

- Consider radical radiotherapy or chemoradiotherapy in patients with T1–4N2 (bulky or fixed) M0 disease. [B]
- Consider surgery as part of multimodality management in patients with T1–3N2 (non-fixed, non-bulky, single zone) M0 disease. [B]

Research recommendation

- Consider further randomised trials of surgery added to multimodality management in patients with multi-zone N2 disease to establish if any subgroups of patients might benefit more from the addition of surgery.

1.2.4 N3 disease

N3 disease describes any metastatic involvement of contralateral mediastinal or hilar nodes or any scalene or supraclavicular nodes. Based on limited available evidence in support of radical management, the standard treatment in this group of patients is chemotherapy and/or radiotherapy. Feasibility studies have recently reported favourable outcomes with induction regimens, with impressive 5-year survival results ranging from 40% to 52%.

Research recommendation

- Consider clinical trials of radical treatment for patients with T1–4N3M0 disease.

1.2.5 M1 disease

M1a designation is assigned to the presence of distant metastases by virtue of a separate tumour nodule in the contralateral tumour, with pleural or pericardial involvement. The results of surgery for multifocal lung cancer are discussed in section 1.2.6. The management of patients with positive cytology of pleural or pericardial effusion is palliative.

M1b designation is assigned to distant metastases, and management of this subset is palliative. It is important to note that the survival of patients with pathological stage IV disease is higher than patients with IIIIB disease in the seventh edition of the TNM classification of lung tumours. This phenomenon may be explained by the selection of specific subgroups who underwent surgical management.

Research recommendation

- Consider clinical trials of radical treatment for patients with M1a and M1b disease.

1.2.6 Bronchioloalveolar carcinoma

Considerable interest has been generated in this tumour subtype of adenocarcinoma, particularly after its redefinition in 1999. Specifically, Noguchi et al. reported 100% 5-year survival in patients with this tumour subtype, underpinning the reclassification of bronchioloalveolar carcinoma (BAC) as essentially adenocarcinoma-in-situ. Since true BAC cannot be confidently diagnosed on anything other than a complete resection, allowing full lesion examination to rule out invasion in the tumour, a preoperative diagnosis of BAC is presumptive.
and based on appropriate radiology (pure localised ‘ground glass’ lesions) and, in some cases, consistent pathology. It is also worth noting that, if limited small biopsy samples are available, a mucinous BAC pattern adenocarcinoma carries a higher risk of being multifocal/more advanced than non-mucinous BAC. Numerous reports have been published, affirming excellent postoperative survival in patients, not only with pure true BAC as currently defined, but also in those with small peripheral tumours in which a BAC component was prominent, and in resected multifocal BAC pattern disease.

Based on these reports, opinions are emerging to suggest that this tumour subtype has a better than expected prognosis by current staging classification, and lesser (sublobar resections) forms of management may be acceptable for multifocal disease. It is important to recognise that good results are not uniform and are critically dependent on accurate contemporaneous classification and reporting. It must also be realised that older reports on BAC will not refer to tumours as adenocarcinoma in all other instances as ‘lepidic growth’ and introducing a category of minimally invasive adenocarcinoma. At the time of writing is seems highly likely that these proposals will be incorporated into the next WHO Lung Cancer classification.

**Recommendations**

- Offer suitable patients with single-site bronchioloalveolar carcinoma anatomical lung resection. [C]
- Consider multiple wedge resections in suitable patients with a limited number of sites of bronchioloalveolar carcinoma. [C]

**1.2.7 Open and close thoracotomy**

In the UK, open and close thoracotomy rates have been steadily declining from more than 20% in the early 1980s to a national average of approximately 6% in 2005. This has been attributed to improvements in preoperative imaging and hence case selection. While the declining proportion represents an improvement, a reduction to 0% would imply extreme case selection, and patients who may be technically surgically resectable would be denied the opportunity for surgery, especially where there are difficulties in differentiating between T3 and T4 (section 1.1.1.2). The current national average is approximately 5%.

**Recommendation**

- Surgical units should have an open and close thoracotomy rate of around 5%. [D]

**SECTION 2: SURGERY**

**2.1 Assessment of the risks of surgery**

In this section a tripartite risk assessment model is presented that considers risks of operative mortality, risk of perioperative myocardial events and risk of postoperative dyspnoea (figure 2). Unlike previous guidelines, the recommendations facilitate the calculation and assessment of individual outcomes that may be discussed by the MDT and with the patient.

**2.1.1 Risk assessment for operative mortality**

The ability to estimate the risk of in-hospital death is one of the most important considerations for surgeons and patients when evaluating the option of surgery for lung cancer. In-hospital death after lobectomy for cancer in the UK was reported as 2.6% in 2003. The 30-day mortality for lobectomy and pneumonectomy in England from the National Lung Cancer Audit is 2.3% and 5.8%, respectively.

An ideal model to estimate the risk of death would have a high degree of discrimination within the applied population, be simple to use and be reproducible. As the in-hospital mortality rates are low, large numbers (multi-institutional or multinational studies) would be required to develop these models. Risk stratification for death in thoracic surgery thus remains relatively rudimentary. While there is a large body of work on factors that influence death after thoracic surgery, most either explore only individual variables (not a global risk model), have composite outcomes (rather than death alone) or do not contain sufficiently large numbers to produce a robust model. Among the largest series are the European Society of Thoracic Surgeons (ESTS) risk model that had 3426 patients with 66 deaths; the Veterans Affairs model with 3516 patients with 184 deaths.

Thoracoscore is currently the largest and most discriminating model, and was developed by the French Society of Thoracic and Cardiovascular Surgery on 15 183 patients with 338 deaths with a corresponding c-index of 0.86 in the validation dataset. Apart from internal validation, it has also been validated in a North American cohort with a similar c-index of 0.84. It is a logistic regression-derived model with nine variables (age, sex, American Society of Anesthesiologists (ASA) score, performance status, dyspnoea score, priority of surgery, extent of surgery, malignant diagnosis and a composite comorbidity score, see appendix 5). The performance of Thoracoscore exceeds that of the logistic EuroSCORE, a widely used model in cardiac surgery.

Although a number of studies report an association with increasing age and risk of hospital death and complications, age alone should not exclude a patient from surgery as good outcomes have been reported with appropriate case selection. A recent study has reported that elderly patients, while being aware of their lower health status preoperatively (they had poorer ECOG performance status and...
ASA scores compared with the younger subjects), had no significant differences in their quality of life at 8 months after surgery.\textsuperscript{106[2+]}

**Recommendation**

- Consider using a global risk score such as Thoracoscore to estimate the risk of death when evaluating and consenting patients with lung cancer for surgery. [C]

### 2.1.2. Risk assessment for cardiovascular morbidity

#### Clinical assessment and risk stratification

Myocardial infarction is a major cause of mortality after non-cardiac surgery. The risk of cardiac death or non-fatal myocardial infarction associated with lung resection is generally 1\textendash;5\% and is ranked as intermediate risk by the revised 2007 American College of Cardiology and the American Heart Association (ACC/AHA) guidelines on cardiovascular evaluation before non-cardiac surgery.\textsuperscript{107[N/A]} The current evidence base that guides clinical management of the specific thoracic surgical patient with coronary artery disease is limited.

The history (including assessment of functional status), physical examination and resting ECG are prerequisites for cardiac risk assessment as defined by the ACC/AHA in 2007.\textsuperscript{108[N/A]} All patients with an audible murmur or unexplained dyspnoea should also have an echocardiogram. The first step in cardiac risk assessment is to identify patients with an active cardiac condition, as they all require evaluation by a cardiologist and correction before surgery (table 3).

In patients who do not have an active cardiac condition, risk assessment is performed using the revised cardiac index (table 4), a validated model with receiver operator characteristic (ROC) area under the curve (AUC) of 0.81.\textsuperscript{109[2++]}

Patients with \(\geq 2\) risk factors and good cardiac functional capacity (able to climb a flight of stairs without cardiac symptoms) can proceed to surgery without further investigations. Patients with poor cardiac functional capacity or with \(\geq 3\) risk factors should have further investigations to screen for reversible cardiac ischaemia (eg, exercise stress testing, exercise thallium scan) and, if necessary,cardiology review prior to surgery.

**Recommendations**

- Use the American College of Cardiology guidelines 2007 as a basis for assessing perioperative cardiovascular risk. [C]
- Avoid lung resection within 30 days of myocardial infarction. [B]
- Seek a cardiology review in patients with an active cardiac condition or \(\geq 3\) risk factors or poor cardiac functional capacity. [C]
- Offer surgery without further investigations to patients with \(\leq 2\) risk factors and good cardiac functional capacity. [B]

### Optimising medical therapy

Patients with coronary disease should have their medical therapy and secondary prophylaxis optimised well in advance of the surgery. Although the ACC/AHA 2007 recommendations advocate the use of periprocedural β blockers, the results from a meta-analysis of 33 trials failed to demonstrate any significant reduction in mortality or heart failure.\textsuperscript{110[1++]} The results indicated a decrease in non-fatal myocardial infarction and ischaemia at the expense of an increase in non-fatal strokes. However, precipitous withdrawal of ongoing β blocker therapy is not recommended as this may be hazardous.\textsuperscript{111[3]} Further studies are required to guide the management of patients with coexisting coronary disease who are undergoing thoracic surgery.

#### Table 3 Active cardiac conditions

<table>
<thead>
<tr>
<th>Condition</th>
<th>Examples</th>
</tr>
</thead>
</table>
| Unstable coronary syndromes | Unstable or severe angina—CCS class III or IV\*
Recent MI† |
| Decompensated heart failure | NYHA functional class IV
Worsening heart failure
New onset heart failure |
| Significant arrhythmias | High-grade atrioventricular block
Mobitz II atrioventricular block
Third degree atrioventricular heart block
Symptomatic ventricular arrhythmias
Supraventricular arrhythmias including atrial fibrillation with uncontrolled ventricular rate: HR >100 beats/min at rest
Symptomatic bradycardia
Newly recognised ventricular tachycardia |
| Severe heart valve disease | Severe aortic stenosis: mean pressure gradient >40 mm Hg, aortic valve area <1.0 cm\(^2\) or symptomatic
Symptomatic mitral stenosis: progressive dyspnoea on exertion, exertional presyncope or heart failure |

\*May include ‘stable’ angina in patients who are unusually sedentary.
†The American College of Cardiology National Database Library defines recent MI as >7 days but ≤1 month within 30 days.
CCS, Canadian Cardiovascular Society grading for angina pectoris; HR, heart rate; MI, myocardial infarction; NYHA, New York Heart Association.

#### Table 4 Revised cardiac risk index

<table>
<thead>
<tr>
<th>Number of factors</th>
<th>Risk of major cardiac complication*</th>
</tr>
</thead>
<tbody>
<tr>
<td>0</td>
<td>0.4%</td>
</tr>
<tr>
<td>1</td>
<td>1%</td>
</tr>
<tr>
<td>2</td>
<td>7%</td>
</tr>
<tr>
<td>≥3</td>
<td>11%</td>
</tr>
</tbody>
</table>

Risk factors: high-risk type of surgery (includes all thoracic surgery), ischaemic heart disease, history of congestive cardiac failure, history of cerebrovascular disease, insulin therapy for diabetes, preoperative serum creatinine >177 μmol/l.

*Cardiac complications defined as myocardial infarction, pulmonary oedema, ventricular fibrillation or primary cardiac arrest, complete heart block. The risks have been quoted from the validation cohort.

---

**Thorax** 2010;65(Suppl III):iii1–iii27. doi:10.1136/thx.2010.145938

iii11
stent should be considered to avoid dual antiplatelet therapy (aspirin and clopidogrel) at the time of lung resection.

**Recommendations**

- Discuss management of patients with a coronary stent with a cardiologist to determine perioperative antiplatelet management. [C]
- Consider patients with chronic stable angina and conventional ACC/AHA indications for treatment (coronary artery bypass grafting and percutaneous coronary intervention) for revascularisation prior to thoracic surgery. [C]

### 2.1.3 Assessment of lung function

Evaluation of lung function is an important aspect of preoperative assessment to estimate the risk of operative mortality and impact of lung resection on quality of life, especially in relation to unacceptable post-resection dyspnoea (see section 2.2.1.1 for estimation of predicted postoperative lung function in relation to extent of resection).

A large number of studies have been published addressing the contribution of lung function to operative mortality risk, most citing an optimum cut-off of postoperative predicted forced expiratory volume in 1 s (FEV1) of 40%. However, many were conducted with sample sizes too small to provide any precision to ascertain the independent impact of FEV1 on in-hospital mortality. Results from over 15,000 patients undergoing thoracic surgery in the French registry suggested FEV1 as a surrogate for performance status rather than an independent predictive factor for perioperative death (see section 2.1.1). This section focuses primarily on the utility of lung function as a predictor of postoperative dyspnoea.

#### Dynamic lung volumes and transfer factor

Both FEV1 and carbon monoxide transfer factor (TLCO) have been previously identified as important predictors of postoperative morbidity and death. Recent data revealed poor correlation (coefficient 0.38) between FEV1 and TLCO, reflecting the fact that they measure very different aspects of lung function. It has been suggested that lung function tests alone overestimate the decrease in functional capacity after lung resection. Studies now suggest that transfer factor is an important predictor of postoperative morbidity despite normal spirometry. In light of this evidence, spirometry alone cannot be considered sufficient unless within normal limits in patients who also have good exercise tolerance. The GDC therefore chose to recommend the measurement of TLCO in all patients.

Previous guidelines advocated a stepwise approach in assessment of lung function prior to resection. The 2001 BTS guidelines were based on recommendations on a lower limit of postoperative predicted FEV1 of 40%, but studies have since reported poor correlation between postoperative predicted FEV1 and TLCO with composite quality of life score. These data led the GDC to question the 40% lower limit. Currently there are few data that provide guidance on a lower limit of lung function which predicts an acceptable degree of postoperative dyspnoea and quality of life. A study of 255 consecutive patients using a lower cut-off point of postoperative predicted FEV1 and TLCO of 30% for the selection of patients undergoing lung resection reported an acceptable mortality rate of 4%, and observed that actual postoperative FEV1 and TLCO are higher than predicted postoperative values achieved using the method of segment counting. However, this study did not specifically address the risk of unacceptable postoperative dyspnoea.

The risk of postoperative morbidity is a decision that has to be tailored to the expectations and wishes of the patient; lowering lung function thresholds allows more patients to undergo surgery but increases the risk of unacceptable postoperative dyspnoea and impaired quality of life. Any recommendations must therefore reflect the degree of risk rather than a firm cut-off.

**Recommendations**

- Measure lung carbon monoxide transfer factor (TLCO) in all patients regardless of spirometric values. [C]
- Offer surgical resection to patients with low risk of postoperative dyspnoea. [C]
- Offer surgical resection to patients at moderate to high risk of postoperative dyspnoea if they are aware of and accept the risks of dyspnoea and associated complications. [D]

#### 2.1.3.1 Split lung function testing

Different techniques have been used to predict postoperative lung function including spirometry, quantitative ventilation and perfusion scintigraphy. In practice there are difficulties in interpreting the contribution of individual lobes to overall ventilation or perfusion and lack of additional information compared with segment counting alone for patients being considered for lobectomy. Recent data revealed poor correlation (coefficient 0.38) between FEV1 and TLCO, reflecting the fact that they measure very different aspects of lung function. It has been suggested that lung function tests alone overestimate the decrease in functional capacity after lung resection. Studies now suggest that transfer factor is an important predictor of postoperative morbidity despite normal spirometry. In light of this evidence, spirometry alone cannot be considered sufficient unless within normal limits in patients who also have good exercise tolerance. The GDC therefore chose to recommend the measurement of TLCO in all patients.

Although quantitative CT scanning has been reported to be simpler and more accurate in the prediction of postoperative FEV1 in patients undergoing pulmonary resection, dynamic perfusion MRI currently has the best reported test performance compared with qualitative CT and perfusion SPECT and may be at least as accurate as quantitative CT.

**Recommendations**

- Consider using ventilation scintigraphy or perfusion scintigraphy to predict postoperative lung function if a ventilation or perfusion mismatch is suspected. [C]
- Consider using quantitative CT or MRI to predict postoperative lung function if the facility is available. [C]

#### 2.1.3.2 Exercise testing

To assist the prediction of surgical outcome, a range of cardio-pulmonary exercise tests has been used. These include assessments of exercise capacity such as walk tests and stair climbing and formal measurements of cardiopulmonary function such as measurement of peak oxygen consumption (VO2max).

**6 and 12 min walk tests.** Good performance on the 6 min walk test and stair climbing have been associated with improving surgical outcomes and have been reported to be similar predictors of mortality to formal exercise testing in patients with chronic obstructive pulmonary disease (COPD) and pulmonary hypertension. The distance walked in 12 min was reported to be a reliable approximation to formal oxygen consumption (VO2) estimation.
in patients with COPD and more closely correlated than 6, 4 or 2 min walking tests.\textsuperscript{143[2+]}. However, the distance achieved on the 12 min walk test has not been reported to be predictive of complications after lung resection.\textsuperscript{116[2-],144[3]}

**Shuttle walk test.** The shuttle walk test is the distance measured by walking a 10 m distance usually between two cones at a pace that is progressively increased. This test has good reproducibility and correlates well with formal cardiopulmonary exercising testing (VO\textsubscript{2max}).\textsuperscript{145[2-],146[4]} Previous BTS recommendations that the inability to walk 25 shuttles classifies patients as high risk has not been reproduced by prospective study.\textsuperscript{147[2+]}. Some authors report that shuttle walk distance may be useful to stratify low-risk groups (ability to walk >400 m) who would not need further formal cardiopulmonary exercise testing.\textsuperscript{148[2+]}

**Stair climbing.** A number of authors have reported on the association between stair climbing and surgical outcomes.\textsuperscript{140[2-],149[2-],150[4],151[2-],152[2+]}. However, the data are difficult to interpret as there is a lack of standardisation of the height of the stairs, the ceiling heights, different parameters used in the assessment (e.g., oxygen saturations, extent of lung resection) and different outcomes.

**Cardiopulmonary exercise testing.** Formal cardiopulmonary exercise testing can be performed using treadmill (walking) or cycling and the most studied parameter is VO\textsubscript{2max}.\textsuperscript{151[2-],153[2-],154[2+],155[2-],156[2+],157[2-],158[2-],159[2-],160[3],161[2-],162[2-],163[2-],164[4],165[2-],166[3],167[2+],168[2-]} A complete review of the primary evidence was undertaken to define the role of cardiopulmonary exercise testing. Currently, there are no good data to inform on the discriminating value of VO\textsubscript{2max} to predict the development of unacceptable postoperative dyspnoea.

Meta-analysis has confirmed the finding that lower levels of VO\textsubscript{2max} are associated with increasing ‘complications’ after lung resection.\textsuperscript{169[2+]} However, numerous values have been used to define ‘prohibitive risk’ for lung surgery, and the studies are difficult to interpret owing to the widespread use of composite endpoints. When scrutinised, individual endpoints included lobar collapse, high levels of carbon dioxide tension (PCO\textsubscript{2}), arrhythmia and readmission to ICU. It is doubtful that many patients would consider the risk of developing these complications as ‘prohibitive’ for surgical resection.

With sample sizes ranging from 8 to 160 patients\textsuperscript{169[2+] and an average death rate of 2.6% for lobectomy, the discriminating cut-off points for VO\textsubscript{2max} to predict death is likely to be poor and, without valid risk adjustment, it is not possible to estimate an independent contribution of VO\textsubscript{2max}. The arbitrary use of cut-off values for defining patient groups with no adverse outcome carries a large degree of imprecision; for example, the 95% binomial CI of no adverse outcomes in a typical sample of 30 patients would be 0–13.6%.

Perhaps the best conducted study was the Cancer and Leukemia Group B (CALGB) Protocol 9238 in which 405 patients were classified into low, high and very high risk groups. Of the 68 patients in the very high risk group (VO\textsubscript{2max} <15 mL/kg/min), surgery was only undertaken at the ‘physician’s discretion’ with an operative mortality rate of 4% and no difference in postoperative complication rate. A central message from this study was that, in patients in the very high risk subgroup who underwent lung resection, the median survival was 36 months compared with 15.8 months for those in the same risk group who did not undergo surgical resection (p<0.001).\textsuperscript{170[2+]} The evidence for cardiopulmonary exercise testing providing a useful definition of ‘high risk’ is therefore limited and there are no data available to show how it can help predict unacceptable levels of postoperative dyspnoea.

**Recommendations**

- Consider using shuttle walk testing as functional assessment in patients with moderate to high risk of postoperative dyspnoea using a distance walked of >400 m as a cut-off for good function. [C]
- Consider cardiopulmonary exercise testing to measure peak oxygen consumption as functional assessment in patients with moderate to high risk of postoperative dyspnoea using >15 mL/kg/min as a cut-off for good function. [D]

**Research recommendation**

- Further studies with specific outcomes are required to define the role of exercise testing in the selection of patients for surgery.

### 2.1.4 Postoperative quality of life/dyspnoea

Lung cancer is associated with the most disruption to quality of life compared with other chronic diseases\textsuperscript{171[5]} or cancers.\textsuperscript{172[5]} and the reduction may persist for more than 5 years.\textsuperscript{173[5]} The physical domains of quality of life deteriorate early after lung cancer surgery but improve to near baseline by 6 months.\textsuperscript{174[5],175[2+],176[5],177[2+],178[2+],179[2+],180[2+],181[3]} Pneumonectomy, however, is associated with both a poorer quality of life\textsuperscript{179[2-],180[2+]} for a longer duration\textsuperscript{178[2+],179[2-],181[3]} compared with lobectomy or bilobectomy. When pneumonectomy can be avoided but there is the potential for an increased risk of recurrence, this should be explained to patients so that they can make a choice.

Traditional parameters used to assess the postoperative cardiorespiratory function do not correlate well with the quality of life reported by patients.\textsuperscript{178[2+] and Although it has been suggested that quality of life after surgery may be related to cardiopulmonary fitness,\textsuperscript{182[3]} pulmonary function assessment alone is a poor predictor of patients’ perceptions of physical disruptions in day-to-day activities.\textsuperscript{120[2+],183[5]} Currently, it is thought that respiratory symptom burden rather than ventilatory impairment contributes to diminished quality of life.\textsuperscript{183[5]} As discrepancies may exist between patients’ perception about their residual physical and emotional status and objective functional measures, lung function tests and exercise tests cannot be taken as sole surrogates for quality of life evaluation. A quality of life instrument should always be used.

Other identified risks factors for poor postoperative quality of life include preoperative dyspnoea and the administration of postoperative chemotherapy.\textsuperscript{184[2-]} The influence of increasing age is less clear, with some studies reporting that elderly patients fail to make a complete recovery\textsuperscript{185[8]} and others reporting no difference compared with their younger counterparts.\textsuperscript{106[2+]} A risk assessment algorithm for postoperative dyspnoea is shown in figure 3.

**Recommendations**

- Avoid pneumonectomy where possible by performing bronchoangioplastic resection or non-anatomical resection. [C]
- Avoid taking pulmonary function and exercise tests as sole surrogates for quality of life evaluation. [C]
- When estimating quality of life, use a validated instrument. [D]
**Recommendation**

- Consider patients with moderate to high risk of postoperative dyspnoea for lung parenchymal sparing surgery. [D]

### 2.2.1.2 Bronchoplastic and angioplastic resections

Bronchoplastic resection refers to the resections that include the main bronchus or bronchus intermedius, usually with a complete ring of airway with continuity restored by the re-anastomosis of proximal and distal airway lumens. Angioplastic resections refer to resections that involve the main pulmonary artery with continuity restored by end-to-end anastomosis or reconstruction.

Bronchoplastic resection is usually used in the setting of low-grade airway tumours such as typical carcinoid tumour (bronchial sleeve resection) or to spare lung parenchyma—for example, in the setting of lung cancer to avoid pneumonectomy (sleeve lobectomy). Lower mortality and lower local recurrence rates have been reported in a series comparing the outcomes of sleeve lobectomy with pneumonectomy. Angioplastic resections are usually employed in the setting of lung parenchymal sparing surgery.

While there may be technical advantages to lung parenchymal sparing surgery, the use of this range of procedures is generally uncommon and may be technically challenging.

### Recommendation

- Consider bronchoangioplastic procedures in suitable patients to preserve pulmonary function. [D]

### 2.2.1.3 Sublobar resections

Sublobar resections generally refer to wedge resections and segmental resections. They are usually performed as an alternative to lobectomy in patients with peripheral tumours with limited pulmonary reserve. Wedge resection entails the macroscopic clearance of the tumour with a surrounding margin of normal lung tissue and does not follow anatomical boundaries, whereas segmental resection involves the division of vessels and bronchi to a distinct anatomical segment(s). Segmental resection removes draining lymphatics and veins and might therefore result in lower recurrence rates, although there is no evidence for this. Segmental resection may not always be technically feasible and is best suited to the left upper lobe (lingula, apico-posterior and anterior segments) and the apical segment of both lower lobes. Sublobar resections for patients with multiple foci of bronchioloalveolar carcinoma have been discussed in section 1.2.6.

In the only randomised trial comparing lobectomy with sublobar resection in patients with T1N0 tumours, the authors report similar overall survival but increased local recurrence at 3 years with limited resection. Angioplastic resections refer to resections that involve the main pulmonary artery with continuity restored by end-to-end anastomosis or reconstruction.

### Recommendation

- Consider patients with limited pulmonary reserve for sublobar resection as an acceptable alternative to lobectomy. [B]

### Research recommendation

- Consider randomised trials of segmental resection versus wedge resection.

### 2.2.1.4 Combined lung volume reduction surgery

Randomised trials of lung volume reduction surgery report improved lung function after surgical resection in patients with severe heterogeneous emphysema. Entry criteria in the largest clinical trial to date included patients with a preoperative FEV₁ of only 20–40% predicted, and lung...
function was shown to improve after surgical resection. Therefore, if lung cancer is isolated to an area of severe heterogeneous emphysema, it seems reasonable to use criteria currently used for lung volume reduction surgery (preoperative FEV1 or TLCO >20% predicted) to select patients for lung resection.\textsuperscript{194[D]} Potential benefit should be both improvement in symptoms due to emphysema and curative resection.

**Recommendation**
- Consider patients with concomitant lung cancer within severe heterogeneous emphysema for lung resection based on lung volume reduction surgery criteria. [B]

2.2.2 Lymph node management

Intuitively, surgeons should be moving towards increasing the accuracy of cancer staging by systematic nodal dissection. However, there is considerable variation in practice, from no lymph node sampling through lobe-specific sampling to systematic nodal dissection. Postoperative morbidity is usually cited against the use of routine systematic nodal dissection and, in response to this, the results of the American ACOSOG Z50 trial confirm that patients randomised to complete mediastinal lymphadenectomy had little added morbidity compared with those who underwent lymph node sampling.\textsuperscript{195[A]} Two trials comparing systematic nodal dissection with lymph node sampling reported better survival in patients randomised to systematic nodal dissection.\textsuperscript{196[D],197[D]}

Currently, the International Union Against Cancer (UICC) recommends that at least six lymph node stations should be removed or sampled before the confirmation of pN0 status.\textsuperscript{61[N/A]} Three of these nodes/stations should be mediastinal (including the subcarinal station) and three should be from N1 stations.

**Recommendations**
- Perform systematic nodal dissection in all patients undergoing resection for lung cancer. [A]
- Remove or sample a minimum of six lymph nodes or stations. [D]

2.3 Chemotherapy

2.3.1 Preoperative chemotherapy

Preoperative (neoadjuvant/induction) chemotherapy offers the opportunity to downstage the tumour prior to surgery, assess the response to chemotherapy and thereby prognosis, and potentially control micrometastatic disease at an earlier time point including mitigation of any pro-oncogenic effects of surgery.\textsuperscript{198[D,4],199[D]} This paradigm has been adopted in other cancers (breast, gastric, oesophageal and rectal) with considerable success. However, studies with non-small cell lung cancer have been dogged by poor accrual, perhaps due to an inherent belief that early surgery is required to prevent disease progression.

A number of studies of preoperative chemotherapy (versus surgery alone) were closed early due to large survival benefits reported for patients randomised to preoperative chemotherapy.\textsuperscript{200[D],201[D]} Subsequent studies continued to demonstrate a survival advantage for preoperative chemotherapy, albeit not reaching statistical significance, and were likely to have been underpowered to detect even modest effects.\textsuperscript{202[D]}

The largest trial comparing preoperative chemotherapy and surgery versus surgery alone randomised 519 patients, confirming the feasibility of this approach with 75% of patients completing the full course of chemotherapy, with a progression rate of only 2%.\textsuperscript{203[A]} However, there was no difference in survival between the two groups (HR 1.02, 95% CI 0.8 to 1.31, p=0.86) although 64% of patients in the chemotherapy arm had stage 1 disease, probably less likely to benefit from chemotherapy.\textsuperscript{204[N/A],205[D]} Pooling results with all other preoperative studies by meta-analysis obtained borderline significance with an overall reduction in HR of death by 12% (HR 0.88, 95% CI 0.76 to 1.01, p=0.07).\textsuperscript{202[D]} which is similar to that of postoperative chemotherapy.\textsuperscript{204[N/A]}

Given the relatively small number of studies of preoperative chemotherapy compared with the evidence base for postoperative chemotherapy, residual uncertainties about the overall benefits on pooled data and concern of progression on treatment, routine clinical administration of preoperative chemotherapy is not recommended.

**Recommendation**
- Patients with resectable lung cancer should not routinely be offered preoperative chemotherapy. [B]

2.3.2 Postoperative chemotherapy

Data from five multicentre studies have established the survival benefit of postoperative (adjuvant) platinum-based chemotherapy in selected patients.\textsuperscript{79[D],206[D],207[D],208[D],209[D]} Currently, the evidence in this section has been collated from clinical trials that have used the 6th Edition of the TNM classification of lung cancer, so it is important to appreciate the limitations with respect to the application of the recommendation of patients by stage criteria. There is no evidence of benefit of postoperative chemotherapy in stage IA non-small cell lung cancer in a western population.\textsuperscript{204[N/A]}

For stage IB non-small cell lung cancer, the evidence is controversial. Kato et al report a survival benefit in patients with adenocarcinoma treated with Uracil-Tegafur, but it is thought that that this may reflect a local epiphenomenon as this study was based on a pharmacogenetically distinct (Japanese) population.\textsuperscript{206[D]} The CALGB 9633 study was terminated early due to interim analysis demonstrating significant improvement in overall and disease-free survival; however, more mature data showed no ongoing benefit to overall survival, although the benefits were maintained with disease-free survival except in tumours of >4 cm where a survival benefit was observed.\textsuperscript{210[D]} In the IB subgroups from larger trials, no benefit was observed on individual patient data meta-analysis.\textsuperscript{84[D]} Treatment should be considered on an individual basis (eg, patients with tumours >4 cm), noting the differences between the 6th and 7th edition TNM staging systems. It should be noted that there are few data to guide on the use of chemotherapy in patients who are found to have 7th edition TNM T4 tumours by virtue of additional tumour in a different ipsilateral lobe. Such patients should, intuitively, receive postoperative chemotherapy, but the GDC felt there was insufficient evidence to make a recommendation.

For stage II and III non-small cell lung cancer, there is a strong body of evidence supporting the use of postoperative adjuvant chemotherapy with an HR of overall survival ranging from 0.74 to 0.89.\textsuperscript{84[D],211[D],212[D],213[D],214[D],215[D]} Despite the role of adjuvant chemotherapy in potentially curatively resected non-small cell lung cancer, survival remains relatively poor and efforts aimed at accruing patients into clinical trials of novel therapeutics are warranted.

**Selection of chemotherapy regimen**

Current evidence supports the use of cisplatin-based chemotherapy, and the Lung Adjuvant Cisplatin Evaluation (LACE) meta-analysis suggested that cisplatin and vinorelbine may be the superior regimen.\textsuperscript{84[D]} In the current postoperative trials
3–4 cycles of chemotherapy were used with scheduling based on
4- or 3-weekly cycles depending on the chosen regimen. The
JBR10 study reported that chemotherapy was poorly tolerated
with only 48% completing four cycles of treatment.209[1+] Currently,
the cisplatin-vinorelbine combination is the most
widely adopted postoperative schedule in the UK. In vinorelbine-
based studies,209[1+],217[1++] vinorelbine was given 4-weekly with
cisplatin. However, a 3-weekly day 1 and day 8 schedule (already
used in many parts of the UK for advanced disease) may be more
convenient, better tolerated and have similar efficacy.218[1+]

Although comorbidities increase with age, pooled data from
LACE indicate that elderly patients also benefit from postoperative
chemotherapy, although the starting and total dose of cisplatin
may be significantly lower than their younger counterparts.84[1++]

Recommendations

- Offer postoperative chemotherapy to patients with TNM 7th
dition T1–T3N1–T2MO non-small cell lung cancer. [A]
- Consider postoperative chemotherapy in patients with TNM
7th edition T2–T3NOM0 non-small cell lung cancer with
tumours >4 cm diameter. [B]
- Use a cisplatin-based conjunction therapy regimen in post-
operative chemotherapy. [A]

Research recommendation

- Consider further trials of novel chemotherapeutic agents in
conjunction with surgical resection.

2.4 Postoperative radiotherapy

Effective adjuvant radiotherapy is routinely offered for breast
and rectal cancer improving both local control and survival. The
effectiveness of postoperative radiotherapy (PORT) remains

The PORT Meta-analysis Trialists Group analysed individual
patient data from nine randomised trials (2128 patients) that
compared surgery followed by PORT with surgery alone.219[1++]
The authors reported a 21% relative increase in the risk of death
at 2 years with PORT, reducing the overall survival from 55% to
48% (mortality HR 1.21, 95% CI 1.08 to 1.34, p = 0.001).
Subgroup analyses suggested that PORT could be deleterious in
terms of overall survival, predominantly among patients with
stage I/II and pN0 or pN1 disease whereas, for those with N2
disease, there was no clear evidence of an adverse effect. It is
important to note that the radiotherapy used in these trials
would be regarded as suboptimal by current standards (no CT
scan-based radiotherapy planning, two-dimensional radio-
therapy, use of cobalt-60 equipment, use of spinal cord block, use
of controversial doses and fractionations).

The PORT meta-analysis was updated in 2005 adding the
Troadelphia study,220[1+] which addressed the role of PORT
in patients with stage I disease.221[1+]
The results continued to show PORT to be detrimental overall, with
an 18% relative increase in the risk of death at 2 years. The updated
meta-analysis confirmed that there was no clear evidence of a
detriment in patients with stage III disease treated with PORT.

Two studies not included in the original or updated PORT
meta-analysis showed no treatment-related mortality, a reduc-
tion in local recurrence but no difference in survival.222[1+],223[3]
The results from a non-randomised subanalysis of the Adjuvant
Navelbine International Trialist Association (ANITA) trial79[1++] and
from a Surveillance Epidemiology and End Results (SEER)
retrospective study224[2–] suggest the benefit of PORT in stage IIIA
disease.

It should be noted that the role of PORT in the context of medi-
stinal dissection as opposed to mediastinal sampling is not known.

In summary, there is no indication for PORT based on nodal
status in completely resected disease. However, this is an area of
active research and patients should be offered participation in
randomised trials wherever possible.

The role of PORT in patients with a positive resection margin
(R1 resection) is unknown as there are no randomised trials
examining the role of radiotherapy in this group of patients.225[3],226[4]
PORT is often given in routine practice if
pathological examination shows tumour at the resection margin
on the basis of retrospective series showing a reduction in the
local recurrence rates following PORT227[4],228[3],229[3],230[3]231[4] or
an excess of local recurrence rates without PORT232[3]
However, some retrospective series have shown high local
recurrence rates despite the use of PORT.230[3],233[4] It should also
be noted that a retrospective study showed an adverse impact
of radiotherapy on survival in patients irradiated for positive
margins.227[4]

Microscopic residual disease includes bronchial and extra-
bronchial residual disease. Furthermore, bronchial residual
disease can be divided into mucosal (subdivided into infiltrative
carcinoma or carcinoma-in-situ) and peribronchial (outside the
cartilage) microscopic residual disease. Poorer survival has been
reported in patients with peribronchial disease.241[5] However,
it should be noted that the majority of patients with submucosal
and peribronchial disease have N2 or N3 lymph node meta-
stasy.227[4],233[4] A literature review on this topic suggested that
patients with stage I and II disease and positive margins are
more likely to benefit from PORT than patients with stage III
disease.225[3] Indeed, survival of patients with stage I and II non-
small cell lung cancer and an R1 resection of the bronchial
resection margin is significantly worse compared with the stage-
corrected survival after radical surgery.208[1+] In the former,
survival is limited due to local recurrence.232[3],235[3],237[3]
The negative effect of microscopic residual disease at the bronchial
resection margin in stage III non-small cell lung cancer is less
pronounced. These patients probably die due to disseminated
disease before local recurrence occurs.237[3]

Similarly, patients with submucosal and peribronchial disease are unlikely to
benefit from PORT. It is not possible based on the current
literature to recommend PORT for all patients with residual
microscopic disease at the bronchial resection margin, particu-
larly for stage III non-small cell lung cancer. The potential
benefit of this treatment in terms of reduction of the risk of local
recurrence rate has to be weighed carefully against the risk of
morbidity and mortality related to PORT.

After surgical resection of lung cancer, when delivering PORT
it is crucial to keep the dose to the normal lung tissue to
a minimum.238[4] Ideally, the volume at risk should be delineated
on the radiotherapy planning scan by a clinical oncologist
specialised in thoracic malignancies with the input of the
thoracic surgeon who performed the operation. The optimal
dose/fractionation for PORT is not known, but modern studies
suggest that a dose in the range of 50–55 Gy using conventional
fractionation should be used.220[1+],239[4]

There are few randomised data investigating the benefit of
PORT and its optimal sequencing in the context of adjuvant
chemotherapy. In adjuvant chemotherapy trials allowing the use
of PORT, the radiotherapy was delivered after completion of
adjuvant chemotherapy and did not seem to offset the beneficial
effect of adjuvant chemotherapy.79[1+],208[1+],207[1+]

Recommendations

- Postoperative radiotherapy (PORT) is not indicated after R0
complete resection. [A]
▸ Consider PORT for patients with residual microscopic disease at the resection margin where the benefit of reduction in local recurrence outweighs the risk of mortality and morbidity related to PORT. [C]
▸ Use CT-planned three-dimensional conformal radiotherapy for patients receiving PORT. [B]
▸ Consider PORT after completion of adjuvant chemotherapy. [B]

Research recommendation
▸ Randomised trials looking at the effect of PORT in pN2 non-small cell lung cancer are recommended.

SECTION 3: RADICAL RADIOTHERAPY
3.1 Assessment of the risks of radiotherapy
3.1.1 Risks of radical radiotherapy
When planning radical radiotherapy to the thorax it is crucial to take into account the dose delivered to the normal lung tissue, oesophagus, spinal cord and heart. In order to ensure the maximum sparing of normal tissues, three-dimensional treatment planning is mandatory. However, defining limits of dose tolerated by these tissues is complex as these limits vary according to the total dose delivered, fractionation regimen and use of concurrent chemotherapy. The risk of developing radiotherapy-induced lung toxicity can be estimated by calculating the dose-volume histogram of the lungs, including V20 and mean lung dose.

3.1.2 Lung function assessment
The greatest limitation of thoracic radiotherapy is radiotherapy-induced lung toxicity. It is generally assumed that patients with pre-existing pulmonary disease (particularly COPD) are at increased risk of radiation morbidity, but the data relating premorbid physiology to radiation toxicity are limited. Knowledge of the risks of radiotherapy is usually used to guide the design of radiotherapy treatment plans rather than to decide whether or not to treat. However, in many chemoradiotherapy trials, pulmonary function limits (similar to the limits used for surgical patients) are set for exclusion of patients.

Safe lower limits of respiratory function (FEV1 or TlCO) for radical radiotherapy have not been established and current evidence is insufficient to determine safe lower limits. Radiotherapy planning parameters such as V20 and mean lung dose are effective tools for predicting radiation pneumonitis.

3.2 Radiotherapy and chemoradiotherapy regimens
3.2.1 Early stage disease
Usually patients with early disease are considered for radiotherapy owing to the unacceptable risk of perioperative death, surgical complications or postoperative dyspnoea. In stage I non-small cell lung cancer, conventional radiotherapy is associated with long-term survival rates of 5–50% and local failure rates of 40–70%.

A Cochrane review of 2005 patients with stage I/IIA non-small cell lung cancer from 26 non-randomised studies and 563 patients from a randomised controlled trial concluded that ‘radical radiotherapy appears to result in a better survival than might be expected had treatment not been given’. However, the optimal dose and treatment technique could not be defined.

A clinical trial randomised 563 patients with stage I–IIIB non-small cell lung cancer to either CHART (54 Gy in 36 fractions over 12 days) or conventionally fractionated radiotherapy (60 Gy in 30 fractions over 6 weeks) and reported an improvement in 5-year survival in favour of CHART from 7% to 12%.

The largest series to date reported 5-year overall survival of 71% and local control rate of 84%, which is a variety of doses and fractionations have been used, ranging from 30 Gy in two fractions to 75 Gy in 22 fractions. Treatment of tumours adjacent to a primary or secondary bronchus should be avoided as acute toxicity and symptomatic bronchial stenosis have been reported. The optimal stereotactic radiotherapy regimen has not yet been defined, nor has stereotactic radiotherapy been compared with standard radiotherapy or surgery in randomised trials.

Recommendations
▸ Offer radical radiotherapy to patients with early stage non-small cell lung cancer who have an unacceptable risk of surgical complications. [B]
▸ Consider CHART as a treatment option in patients with early stage non-small cell lung cancer and unacceptable risk of surgical complications. [A]
▸ Consider stereotactic body irradiation in patients with early stage non-small cell lung cancer and unacceptable risk of surgical complications. [C]

3.2.2 Locally advanced disease
3.2.2.1 Patients eligible for concurrent chemoradiotherapy
The literature supports the use of concurrent chemoradiotherapy in patients aged <75 years (patients aged >75 years have not been included in clinical trials), performance status 0–1, with reasonable lung function, without major comorbidities, and for whom the radiotherapy plan produces acceptable normal tissue doses.
A body of evidence supports that, in patients with inoperable stage III non-small cell lung cancer, survival is improved when cisplatin-based chemotherapy is given at the same time as radiotherapy (concurrent chemoradiotherapy).286[1++]

A Cochrane review reported improved survival with cisplatin-based concurrent chemoradiotherapy among patients with inoperable stage III non-small cell lung cancer compared with sequential treatment (RR 0.86, 95% CI 0.78 to 0.95, p=0.003) at the expense of increased radiation oesophagitis.287[1++] Improved 5-year survival in favour of concurrent chemoradiotherapy has also been reported by individual patient data meta-analysis with an absolute improvement of 6.6% from 18.2% with sequential chemoradiotherapy to 24.8% with concurrent chemoradiotherapy.288[1–]

There is currently no consensus on the optimal chemotherapy regimen when combined with radiotherapy. There are data to support the combination of cisplatin-based chemotherapy. A number of regimens have been reported to show acceptable outcome and toxicity profiles.289[1–2],290[1],291[1+],292[1–]

The choice of chemotherapy regimen with concurrent thoracic radiotherapy should be considered based on individual patient characteristics, toxicity profile and local experience.

A meta-analysis of six concurrent chemoradiotherapy trials reported that increasing radiation dose improved both local control and overall survival; however, the optimal radiotherapy regimen has not been defined.293[1++]

To date, no studies have demonstrated any benefit of induction chemotherapy prior to concurrent chemoradiotherapy.290[1–],290[2]. There have been initial reports that the addition of consolidation docetaxel after concurrent treatment was associated with median survival in excess of 20 months in stage III non-small cell lung cancer;294[1–],295[1++] but this was subsequently refuted in a phase III randomised study.296[1–]

### 3.2.2.2 Patients not eligible for concurrent chemoradiotherapy

Sequential chemoradiotherapy with platinum-based chemotherapy is the standard of care in patients with locally advanced non-small cell lung cancer not suitable for concurrent chemoradiotherapy. Three systematic reviews reported superior survival for patients treated with chemotherapy and radiation therapy compared with radiation therapy alone.297[1++],298[1–],299[1–],300[1–],301[1+],302[1+]. The Non-Small Cell Lung Cancer Collaborative Group reported on 22 trials (3035 patients) and showed a 13% reduction in risk of death, equivalent to an absolute benefit of 5% at 5 years, when cisplatin-based chemotherapy was combined with radiation therapy compared with radiation therapy alone.303[1++],304[1++]. The meta-analysis did not provide an answer to the question of the optimal radiotherapy or chemotherapy regimen.

#### Recommendations

- Offer chemoradiotherapy to patients with locally advanced non-small cell lung cancer and good performance status who are unsuitable for surgery. [A]
- Offer selected patients with good performance status concurrent chemoradiotherapy with a cisplatin-based chemotherapy combination. [A]
- Offer patients unsuitable for concurrent chemoradiotherapy sequential chemoradiotherapy. [A]

### 3.2.2.3 Patients not eligible for chemotherapy

Patients who are not candidates for chemotherapy because of significant comorbidity (eg, cardiovascular disease, renal impairment) or poor performance status should be offered radical radiotherapy.

The CHART trial included 60% of patients with stage III–IV disease who reported improved survival with hyperfractionated accelerated radiotherapy compared with conventional radiotherapy.288[1++] However, due to logistic reasons, the CHART regimen is not used in the majority of UK centres.

There are currently no strong data supporting hyperfractionated radiotherapy over conventional radiotherapy. The hypofractionated radiotherapy regimen used widely in the UK consisting of 55 Gy in 20 fractions has not been compared with conventional radiotherapy in patients with locally advanced inoperable non-small cell lung cancer.296[4]

A German trial compared 60 Gy/40 f/2.5 w (CHARTWEL) or 66 Gy/35 f/6.5 w in patients with stage I–III non-small cell lung cancer (84% stage III). No significant difference in local control and overall survival was reported between the CHARTWEL arm and the conventional fractionation arm.299[1++]

#### Recommendation

- Consider CHART as a treatment option for patients with locally advanced non-small cell lung cancer. [A]

### 3.3 Other radical treatment

In early stage disease where patients have significant comorbidities or poor lung function, other radical treatments should be considered and discussed with patients as a valid alternative to high risk of death or postoperative dyspnoea. The evidence base for these approaches is very limited because it has been difficult ethically to justify randomised trials. This should no longer be the case in high-risk patients and properly designed studies in this area are strongly recommended.

#### Research recommendation

- Randomised controlled trials are recommended comparing conventional radical treatment (surgery, radical radiotherapy) with other radical treatments where there is evidence of efficacy in case series.

### 3.3.1 Radiofrequency ablation

Radiofrequency ablation (RFA) for primary lung tumours has developed as a minimally invasive treatment for both radical treatment and palliation. It is well tolerated and complication rates are low. The treatment can be delivered in a single session, usually requiring only a short admission. RFA is suitable for small tumours, usually of 5 cm diameter or less, although larger lesions may be considered suitable in certain circumstances. The medium- and long-term follow-up data suggest survival figures similar to other non-surgical treatment modalities with which it may be compared.

Patients should be selected by the MDT and are usually non-surgical candidates because of the site of the tumour or more commonly because of comorbidity (especially limited cardiorespiratory function). Occasionally patients may simply refuse major surgical treatment or radiotherapy. FDG-PET staging prior to choosing the appropriate treatment modality should be mandatory.

No data have been published so far on the combination of RFA with chemotherapy for early stage non-small cell lung cancer. In studies with attempted RFA for radical management of early stage non-small cell lung cancer, survival data are significantly better than for the patient population treated with a palliative intent. Recently reported long-term survival rates after percutaneous RFA of stage I non-small cell lung cancer were 78% at 1 year, 57% at 2 years, 56% at 5 years, 27% at 4 years and 27% at 5 years.300[3]

These figures are superior to the survival rates from external beam
Consider radical brachytherapy in patients with early invasive non-small cell lung cancer. Recent advances in the field of radiation therapy with hypofractionated high-dose proton beam therapy show competitive survival results, as does stereotactic radiosurgery. A combination of RFA and conventional radiotherapy has already shown better local control and survival rates than radiotherapy alone, with cumulative survival rates of 50% and 39% at the end of 2 years and 5 years, respectively.

3.3.2 Radical brachytherapy
Radical brachytherapy uses high-dose radiotherapy delivered via a catheter inserted at flexible bronchoscopy. Case series have shown that this technique is curative where disease is limited to early mucosal or submucosal disease. Lesions up to 4 mm in depth may be suitable and this technique offers a low morbidity alternative to surgery. Lesions suitable for this treatment are uncommon with current surveillance techniques. The results of randomised trials of autofluorescence bronchoscopy are awaited.

Recommendations
- Consider alternative radical treatment in early stage lung cancer in patients at high risk of morbidity and mortality with conventional radical treatment. [D]
- Consider radical brachytherapy in patients with early invasive mucosal or submucosal non-small cell lung cancer. [D]

SECTION 4: SMALL CELL LUNG CANCER

4.1 Chemoradiotherapy
In general, patients with limited stage small cell lung cancer should be treated with a combination chemotherapy and radiotherapy. The standard chemotherapy regimen is cisplatin and etoposide.

4.1.1 Patients eligible for concurrent chemoradiotherapy
The literature supports the use of concurrent chemoradiotherapy in patients aged <75 years (patients aged >75 years have not been included in clinical trials), performance status 0–1, without major comorbidities and for whom the radiotherapy plan produces acceptable normal tissue doses.

Clinical trials have reported better survival in patients randomised to concurrent chemoradiotherapy compared with sequential chemoradiotherapy. Based on data obtained by meta-analysis, radiotherapy should start before the third cycle of chemotherapy but it is currently unclear if thoracic radiotherapy should commence with the first or the second cycle.

Options for radical radiotherapy in the concurrent setting include twice daily thoracic radiotherapy (45 Gy in 3 weeks) and 40 Gy once daily delivered in 3 weeks. High doses of radiation (≥66 Gy) delivered once daily concurrently with CT are currently under evaluation.

There are limited data supporting the use of conformal radiotherapy without elective nodal irradiation to decrease acute toxicity, an area that should be explored within the context of randomised trials. Patients with any response to chemotherapy or stable disease should be given prophylactic cranial irradiation.

4.1.2 Patients not eligible for concurrent chemoradiotherapy
Patients who are not suitable for concurrent chemoradiotherapy, as outlined above, but eligible for platinum-based chemotherapy should be treated with sequential chemoradiotherapy.

Patients who are not eligible for concurrent chemotherapy should receive 4–6 cycles of platinum-etoposide chemotherapy followed by radical thoracic radiotherapy and prophylactic cranial irradiation. The current UK hypofractionated regimen of 50–55 Gy in 20 fractions has not been formally compared with conventional radiotherapy.

Recommendations
- Offer selected patients with T1–4N0–3M0 limited stage small cell lung cancer both chemotherapy and radiotherapy. [A]
- Offer patients with T1–4N0–3M0 limited stage small cell lung cancer and good performance status concurrent chemoradiotherapy. [A]
- Recommended treatment options for concurrent chemoradiotherapy are twice daily thoracic radiotherapy (45 Gy in 3 weeks) with cisplatin and etoposide and 40 Gy once daily delivered in 3 weeks. [A]
- Offer patients unsuitable for concurrent chemoradiotherapy sequential chemoradiotherapy. [A]
- Offer prophylactic cranial irradiation to patients with response to treatment and stable disease. [A]

4.2 Surgery
The role of surgery for the treatment of limited stage small cell lung carcinoma has been considered inappropriate due to poor overall survival. The only trial to evaluate the role of primary surgery concluded no benefit compared with radiotherapy. In this study, patients were recruited based on bronchial biopsies and complete resection was only achieved in 48% of patients, possibly reflecting the unavailability of CT scanning and non-use of mediastinoscopy. The results were further limited; on intention-to-treat analysis, more than half of the patients in the surgical arm underwent exploratory thoracotomy or no surgery. In view of these limitations, and as it was conducted in an era before the use of CT, the results of this trial cannot be extrapolated into today’s practice.

The only trial to evaluate the role of surgery after response to initial chemotherapy concluded no benefit of adjuvant surgery. Patients who were diagnosed with small cell lung cancer on bronchoscopy, where the origin of the tumour could be identified preoperatively and who responded to initial chemotherapy were randomised to surgery or no additional treatment with an overall 2-year survival of 20% in both arms.

Following from these two trials published in 1972 and 1994, evidence for the role of surgery has been limited to case series, some reporting 5-year survival as high as 52%. The selection criteria and estimated benefit for surgery in current clinical practice remains undefined, and wide differences in opinions currently exist with regard to appropriate surgical selection. To address the role of surgery, patients should be considered for entry into clinical trials when applicable.

Recommendations
- Consider patients with T1–3N0–1M0 small cell lung cancer for surgery as part of multi-modality management. [D]
- Surgical management of patients with T1–3N2M0 small cell lung cancer should only be considered in the context of a clinical trial. [C]

SECTION 5: PROVISION OF TREATMENT OPTIONS
In this guideline, every effort has been made to ensure pragmatic and feasible recommendations in the NHS. It is recognised that delivery of radical treatment in the UK is below that in many equivalent healthcare systems. This guideline supports...
advancement of effective radical treatment and has recommended some treatments that may not be available in all institutions. It is hoped that this will encourage the development of services so that these treatments can be accessed by all patients. The concept of a tripartite risk assessment with this presented to patients to make an informed choice may present some difficulties if the clinician is not willing to undertake the risks of treatment or if complexity of the proposed management cannot be provided locally. With the development of improved services this situation is mitigated but, in the interim, clinicians must be prepared to refer to colleagues who can provide these services. Where radical treatments that push the boundaries are the subject of research, this should be discussed with patients and referrals made for entry into clinical trials.

Recommendation

- All available treatment options, including those that are the subject of research, should be discussed with patients and their carers and the risks and benefits presented so that they may make an informed choice. [D]

Acknowledgements

The GDC is grateful to Lisa Stirk who created search strategies and carried out the online literature searching that formed the evidence base for this document. Committee meeting expenses were funded by the British Thoracic Society.

Competing interests

JE, DW and TW are authors of some of the research evidence used. SAP has received honoraria from Pierre-Fabre. The other authors have no competing interests.

Contributors

EL is Chair of the Guideline Development Committee, performed initial literature review, wrote many sections of the document and edited the document; DB set up and chaired the initial meetings, contributed to several sections, edited the document, produced the quick reference guide and summary of recommendations; MB attended meetings, commented on several sections of the document and contributed the section relating to physiology; JD attended meetings and commented on several sections of the document; JE attended meetings and contributed predominantly to the radiology section; KK commented on the document and wrote the section relating to pathological issues; CF attended meetings and contributed to several sections of the document, especially radical radiotherapy; AM attended meetings and contributed to several sections of the document, especially cardiac risk assessment; JMvG attended meetings and commented on the document; SJ contributed the section of radiofrequency ablation; SAP authored/co-authored several sections and commented on the drafts; NS co-authored the imaging section and commented on several sections of the document; TW attended meetings and contributed to the risk assessment for surgery sections.

Provenance and peer review

The Guideline Development Group held regular meetings over the period from December 2007 to January 2010. The draft guideline was presented at the BTS Winter Meeting in December 2009 and circulated to institutions. It is hoped that this will encourage the development of services so that these treatments can be accessed by all patients. The concept of a tripartite risk assessment with this presented to patients to make an informed choice may present some difficulties if the clinician is not willing to undertake the risks of treatment or if complexity of the proposed management cannot be provided locally. With the development of improved services this situation is mitigated but, in the interim, clinicians must be prepared to refer to colleagues who can provide these services. Where radical treatments that push the boundaries are the subject of research, this should be discussed with patients and referrals made for entry into clinical trials.

REFERENCES


156. Smith TP, Peddle CJ, Thorax 152.


---

**Supplement**

Thorax 2010; 65(Suppl III):iii1–iii27. doi:10.1136/thx.2010.145938 iii23


APPENDIX 1
Topics identified for scope of guideline
1. Diagnosis and staging: How should patients potentially suitable for radical treatment be managed? Include:
   a. Imaging
   b. Bronchoscopic procedures
   c. Endobronchial and endoscopic ultrasound
   d. Mediastinoscopy
   e. Video-assisted thoracic surgery
2. Management of specific disease subsets: How should patients potentially suitable for radical treatment in specific disease subsets be managed? Subsets include:
   a. Early stage disease
   b. T3 disease
   c. N2 disease
   d. Locally advanced disease
3. Assessment of risk: How should patients potentially suitable for radical treatment be assessed for risk? Include:
   a. Operative mortality
   b. Postoperative morbidity
   c. Radical radiotherapy
4. Surgery: What surgical techniques should be used for patients? 
5. Chemotherapy and radiotherapy: How should patients suitable for radical treatment be treated with chemotherapy and radiotherapy? Include:
   a. Radical radiotherapy/chemoradiotherapy
   b. Preoperative and postoperative radiotherapy
   c. Preoperative and postoperative chemotherapy
6. Small cell lung cancer: How should patients with small cell lung cancer be managed if potentially suitable for radical treatment? Include:
   a. Surgery
   b. Radiotherapy
   c. Chemotherapy

Further topics were added after the initial meeting defining scope:
7. Other radical treatments to include:
   a. Stereotactic radiotherapy
   b. Radiofrequency ablation
   c. Radical brachytherapy

APPENDIX 2
Search strategy
Appendix 2 is available online at http://thorax.bmj.com.

APPENDIX 3
Grading of evidence
Studies that were obviously not relevant were excluded in an initial screening process of abstracts. Studies selected for review were appraised as below:
1. Relevance
   a. Is the population studied the same as that covered by the guideline?
   b. Are the outcome measures appropriate and meaningful?
   c. Is the study contemporary enough?
   d. Was the study of adequate size and power?
2. Randomised trials
   a. Was the randomisation process adequate?
   b. Were patients analysed in their randomised groups?
   c. Was the blinding process, if applied?
   d. Were there any differences between the groups compared at baseline?
3. Case—control trials
   a. Were the cases and controls similar at baseline?
   b. Were outcomes measured in the same way for cases and controls?
   c. Were cases selected differently from controls?
4. Studies of diagnostic tests
   a. Was the finding compared with a laudable gold standard?
   b. Was the result of the test blind to the gold standard?
   c. Was the gold standard obtained in all cases?
5. Prognosis or prognostic index studies
   a. Was a relevant group of patients defined at the start?
   b. Was the follow-up period adequate?
   c. Was the prognostic index tested on a fresh set of cases?

Scottish Intercollegiate Guidelines Network (SIGN) levels of evidence

<table>
<thead>
<tr>
<th>Grade</th>
<th>Type of evidence</th>
</tr>
</thead>
<tbody>
<tr>
<td>1+</td>
<td>High quality meta-analyses, systematic reviews of randomised controlled trials (RCTs) or RCTs with a very low risk of bias</td>
</tr>
<tr>
<td>1</td>
<td>Well-conducted meta-analyses, systematic reviews or RCTs with a low risk of bias</td>
</tr>
<tr>
<td>1—</td>
<td>Meta-analyses, systematic reviews or RCTs with a high risk of bias</td>
</tr>
<tr>
<td>2++</td>
<td>High quality systematic reviews of case—control or cohort or studies high quality case—control or cohort studies with a very low risk of confounding or bias and a high probability that the relationship is causal</td>
</tr>
<tr>
<td>2</td>
<td>Well-conducted case—control or cohort studies with a low risk of confounding or bias and a moderate probability that the relationship is causal</td>
</tr>
<tr>
<td>2—</td>
<td>Case—control or cohort studies with a high risk of confounding or bias and a significant risk that the relationship is not causal</td>
</tr>
<tr>
<td>3</td>
<td>Non-analytic studies, for example case reports, case series</td>
</tr>
<tr>
<td>4</td>
<td>Expert opinion</td>
</tr>
</tbody>
</table>

Scottish Intercollegiate Guidelines Network (SIGN) grades of recommendations

<table>
<thead>
<tr>
<th>Grade</th>
<th>Type of publication</th>
</tr>
</thead>
<tbody>
<tr>
<td>A</td>
<td>At least one meta-analysis, systematic review or randomised controlled trial (RCT) rated as 1++ and directly applicable to the target population or A systematic review of RCTs or a body of evidence consisting principally of studies rated as 1++ directly applicable to the target population and demonstrating overall consistency of results</td>
</tr>
<tr>
<td>B</td>
<td>A body of evidence including studies rated as 2++ directly applicable to the target population and demonstrating overall consistency of results or Extrapolated evidence from studies rated as 1++ or 1+</td>
</tr>
<tr>
<td>C</td>
<td>Evidence level 3 or 4 or Extrapolated evidence from studies rated as 2++ Important practical points for which there is no, nor is there likely to be, any research evidence</td>
</tr>
</tbody>
</table>

Additional considerations

The SIGN 50 guidelines take into account grading of comparative versus non-comparative primary evidence. There is no clear guidance on how non-diagnostic studies are listed. In addition, important government statements or reports (eg, GMC guidance, BTS guidelines) come under the “A” category. The GDC felt that this diminishes what are often very influential documents and therefore has classified them as below:

<table>
<thead>
<tr>
<th>Type of publication</th>
<th>Grade</th>
</tr>
</thead>
<tbody>
<tr>
<td>Government/professional body statements or reports</td>
<td>N/A</td>
</tr>
<tr>
<td>Books</td>
<td>N/A</td>
</tr>
<tr>
<td>Phase II randomised controlled trial (RCT) with primary comparison</td>
<td>1—</td>
</tr>
<tr>
<td>Phase II RCT with a non-primary comparative outcome</td>
<td>2++ to 2—</td>
</tr>
<tr>
<td>Diagnostic/validation studies reporting results of calibration</td>
<td>2++ to 2—</td>
</tr>
<tr>
<td>Cohort (prospective) studies with comparative analyses</td>
<td>2++ to 2—</td>
</tr>
<tr>
<td>Economic analyses</td>
<td>2++ to 2—</td>
</tr>
<tr>
<td>Subanalyses from RCTs</td>
<td>2++ to 2—</td>
</tr>
<tr>
<td>Phase II RCT/diagnostic/validation studies demonstrating ‘feasibility’</td>
<td>3</td>
</tr>
<tr>
<td>Cohort (prospective) studies without comparative analyses</td>
<td>3</td>
</tr>
<tr>
<td>Studies reporting research methodology</td>
<td>3</td>
</tr>
<tr>
<td>Studies reporting results of surveys</td>
<td>3</td>
</tr>
<tr>
<td>Editorials, reviews</td>
<td>4</td>
</tr>
</tbody>
</table>

Supplement


APPENDIX 4
Summary of the 7th edition of the TNM staging system in comparison with the 6th edition

<table>
<thead>
<tr>
<th></th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>T1</td>
<td>T1a</td>
<td>Maximum dimension ≤2 cm</td>
</tr>
<tr>
<td></td>
<td>T1b</td>
<td>Maximum dimension 2–3 cm</td>
</tr>
<tr>
<td>T2</td>
<td>T2a</td>
<td>Maximum dimension 3–5 cm</td>
</tr>
<tr>
<td></td>
<td>T2b</td>
<td>Maximum dimension 5–7 cm</td>
</tr>
<tr>
<td></td>
<td>T3</td>
<td>Maximum dimension &gt;7 cm</td>
</tr>
<tr>
<td>T4</td>
<td>T3</td>
<td>Additional nodule in same lobe</td>
</tr>
<tr>
<td>M1</td>
<td>M1a</td>
<td>Additional nodule in ipsilateral different lobe</td>
</tr>
<tr>
<td>M1</td>
<td>M1a</td>
<td>Additional nodules in contralateral lung</td>
</tr>
<tr>
<td>M1</td>
<td>M1a</td>
<td>Malignant pleural or pericardial effusion</td>
</tr>
</tbody>
</table>

Mx is no longer included in the TNM classification, for any tumour site

Surgical stage groupings in 7th TNM classification

<table>
<thead>
<tr>
<th>Stage group</th>
<th>T</th>
<th>N</th>
<th>M</th>
</tr>
</thead>
<tbody>
<tr>
<td>Stage 0</td>
<td>T1</td>
<td>N0</td>
<td>M0</td>
</tr>
<tr>
<td>Stage IA</td>
<td>T1a,b</td>
<td>N0</td>
<td>M0</td>
</tr>
<tr>
<td>Stage IB</td>
<td>T2a</td>
<td>N0</td>
<td>M0</td>
</tr>
<tr>
<td>Stage IIA</td>
<td>T1a,b</td>
<td>N1</td>
<td>M0</td>
</tr>
<tr>
<td></td>
<td>T2a</td>
<td>N1</td>
<td>M0</td>
</tr>
<tr>
<td></td>
<td>T2b</td>
<td>N0</td>
<td>M0</td>
</tr>
<tr>
<td>Stage IIB</td>
<td>T2b</td>
<td>N1</td>
<td>M0</td>
</tr>
<tr>
<td></td>
<td>T3</td>
<td>N0</td>
<td>M0</td>
</tr>
<tr>
<td>Stage IIIA</td>
<td>T1,T2</td>
<td>N2</td>
<td>M0</td>
</tr>
<tr>
<td></td>
<td>T3</td>
<td>N1,N2</td>
<td>M0</td>
</tr>
<tr>
<td>Stage IIIB</td>
<td>T4</td>
<td>N0,N1</td>
<td>M0</td>
</tr>
<tr>
<td>Stage IV</td>
<td>Any T</td>
<td>N3</td>
<td>M0</td>
</tr>
<tr>
<td></td>
<td>Any T</td>
<td>Any N</td>
<td>M1a,b</td>
</tr>
</tbody>
</table>

APPENDIX 5
Thoracoscore

<table>
<thead>
<tr>
<th>Variable</th>
<th>Value</th>
<th>Code</th>
<th>β-coefficient</th>
</tr>
</thead>
<tbody>
<tr>
<td>Age</td>
<td>&lt;55 years</td>
<td>0</td>
<td>0.7679</td>
</tr>
<tr>
<td></td>
<td>55–65 years</td>
<td>1</td>
<td>1.0073</td>
</tr>
<tr>
<td></td>
<td>&gt;65 years</td>
<td>2</td>
<td></td>
</tr>
<tr>
<td>Sex</td>
<td>Female</td>
<td>0</td>
<td>0.4505</td>
</tr>
<tr>
<td></td>
<td>Male</td>
<td>1</td>
<td>0.6057</td>
</tr>
<tr>
<td>ASA score</td>
<td>≤ 3</td>
<td>1</td>
<td>0.689</td>
</tr>
<tr>
<td></td>
<td>≥ 3</td>
<td>1</td>
<td>0.9075</td>
</tr>
<tr>
<td>Performance status</td>
<td>≤ 2</td>
<td>0</td>
<td></td>
</tr>
<tr>
<td></td>
<td>≥ 3</td>
<td>1</td>
<td></td>
</tr>
<tr>
<td>Dyspnoea score</td>
<td>≤ 2</td>
<td>0</td>
<td></td>
</tr>
<tr>
<td></td>
<td>≥ 3</td>
<td>1</td>
<td></td>
</tr>
<tr>
<td>Priority of surgery</td>
<td>Elective</td>
<td>0</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Urgent or emergency</td>
<td>1</td>
<td>0.8443</td>
</tr>
<tr>
<td>Procedure class</td>
<td>Other</td>
<td>0</td>
<td></td>
</tr>
<tr>
<td>Diagnosis group</td>
<td>Benign</td>
<td>0</td>
<td>1.2176</td>
</tr>
<tr>
<td></td>
<td>Malignant</td>
<td>1</td>
<td>1.2423</td>
</tr>
<tr>
<td>Comorbidity score</td>
<td>≤ 2</td>
<td>1</td>
<td>0.7447</td>
</tr>
<tr>
<td></td>
<td>≥ 3</td>
<td>2</td>
<td>0.9065</td>
</tr>
<tr>
<td>Constant</td>
<td></td>
<td></td>
<td>-7.3737</td>
</tr>
</tbody>
</table>

Methods for using the logistic regression model to predict the risk of in-hospital death:
1. Odds are calculated with the patient values and the coefficients are determined from the regression equation:
   \[ \text{Odds} = \exp[-7.3737 + (0.7679 \times \text{code of age is 1 or 0.0073 if code of age is 2}) + (0.4505 \times \text{sex score}) + (0.6057 \times \text{ASA score}) + (0.6890 \times \text{performance status classification}) + (0.9075 \times \text{dyspnoea score}) + (0.8443 \times \text{code for priority of surgery}) + (1.2176 \times \text{procedure class}) + (1.2423 \times \text{diagnosis group}) + (0.7447 \times \text{code of comorbidity is 1 or 0.9065 if code of comorbidity is 2})].

2. The odds for the predicted probability of in-hospital death are calculated: probability = odds/(1 + odds).

ASA, American Society of Anesthesiologists.